ES2543050T3 - Inhibidores de serina/treonina quinasa - Google Patents
Inhibidores de serina/treonina quinasa Download PDFInfo
- Publication number
- ES2543050T3 ES2543050T3 ES12709429.0T ES12709429T ES2543050T3 ES 2543050 T3 ES2543050 T3 ES 2543050T3 ES 12709429 T ES12709429 T ES 12709429T ES 2543050 T3 ES2543050 T3 ES 2543050T3
- Authority
- ES
- Spain
- Prior art keywords
- dihydro
- phenyl
- pyrido
- amide
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940043355 kinase inhibitor Drugs 0.000 title description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 3
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 title description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 title description 2
- -1 benzoimidazolyl Chemical group 0.000 claims abstract description 1179
- 150000001875 compounds Chemical class 0.000 claims abstract description 182
- 239000001257 hydrogen Substances 0.000 claims abstract description 112
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 112
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 68
- 150000003839 salts Chemical class 0.000 claims abstract description 68
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 66
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 64
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 62
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 59
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims abstract description 56
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 56
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract description 52
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims abstract description 47
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 47
- 150000002367 halogens Chemical class 0.000 claims abstract description 47
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 46
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims abstract description 45
- 125000003118 aryl group Chemical group 0.000 claims abstract description 43
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 32
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 28
- 125000000714 pyrimidinyl group Chemical group 0.000 claims abstract description 27
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 26
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 23
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract description 21
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims abstract description 21
- 125000000335 thiazolyl group Chemical group 0.000 claims abstract description 21
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 20
- 125000002252 acyl group Chemical group 0.000 claims abstract description 19
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 19
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 17
- 125000002971 oxazolyl group Chemical group 0.000 claims abstract description 17
- 125000003386 piperidinyl group Chemical group 0.000 claims abstract description 17
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims abstract description 17
- 125000004429 atom Chemical group 0.000 claims abstract description 16
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract description 16
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims abstract description 15
- 125000001041 indolyl group Chemical group 0.000 claims abstract description 15
- 125000002757 morpholinyl group Chemical group 0.000 claims abstract description 15
- 125000003373 pyrazinyl group Chemical group 0.000 claims abstract description 14
- 125000003226 pyrazolyl group Chemical group 0.000 claims abstract description 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 13
- 125000001425 triazolyl group Chemical group 0.000 claims abstract description 13
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims abstract description 12
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract description 12
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims abstract description 12
- 125000004404 heteroalkyl group Chemical group 0.000 claims abstract description 11
- 125000000842 isoxazolyl group Chemical group 0.000 claims abstract description 10
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims abstract description 9
- 125000002883 imidazolyl group Chemical group 0.000 claims abstract description 9
- 125000001786 isothiazolyl group Chemical group 0.000 claims abstract description 9
- 125000001715 oxadiazolyl group Chemical group 0.000 claims abstract description 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 8
- 125000002098 pyridazinyl group Chemical group 0.000 claims abstract description 8
- 125000004306 triazinyl group Chemical group 0.000 claims abstract description 8
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims abstract description 7
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims abstract description 7
- 125000004442 acylamino group Chemical group 0.000 claims abstract description 7
- 125000005843 halogen group Chemical group 0.000 claims abstract description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 7
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 125000002393 azetidinyl group Chemical group 0.000 claims abstract description 6
- 125000004966 cyanoalkyl group Chemical group 0.000 claims abstract description 6
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims abstract description 6
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 claims abstract description 5
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 claims abstract description 5
- 125000003566 oxetanyl group Chemical group 0.000 claims abstract description 5
- 125000004193 piperazinyl group Chemical group 0.000 claims abstract description 5
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 5
- 125000004104 aryloxy group Chemical group 0.000 claims abstract description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 4
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000002253 acid Substances 0.000 claims description 185
- 239000000203 mixture Substances 0.000 claims description 63
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 45
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 44
- 208000035475 disorder Diseases 0.000 claims description 35
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 230000003463 hyperproliferative effect Effects 0.000 claims description 27
- CYZCJADBZVABTN-MRVPVSSYSA-N (2s)-2-amino-2-(3-chloro-4-fluorophenyl)ethanol Chemical compound OC[C@@H](N)C1=CC=C(F)C(Cl)=C1 CYZCJADBZVABTN-MRVPVSSYSA-N 0.000 claims description 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 21
- UJUFOUVXOUYYRG-RXMQYKEDSA-N (1r)-1-(3,4-dichlorophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=C(Cl)C(Cl)=C1 UJUFOUVXOUYYRG-RXMQYKEDSA-N 0.000 claims description 20
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 claims description 18
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 17
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 15
- BLNCONOUQXEUCP-MRVPVSSYSA-N (2s)-2-amino-2-(4-chloro-3-fluorophenyl)ethanol Chemical compound OC[C@@H](N)C1=CC=C(Cl)C(F)=C1 BLNCONOUQXEUCP-MRVPVSSYSA-N 0.000 claims description 14
- QNCIKNHLGKDVGE-UHFFFAOYSA-N 6H-pyrido[3,4-d]pyrimidine-7-carboxylic acid Chemical compound N1=CN=CC=2C1=CN(CC2)C(=O)O QNCIKNHLGKDVGE-UHFFFAOYSA-N 0.000 claims description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 201000009030 Carcinoma Diseases 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 9
- 125000001188 haloalkyl group Chemical group 0.000 claims description 9
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 230000006872 improvement Effects 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 229940127089 cytotoxic agent Drugs 0.000 claims description 7
- CYZCJADBZVABTN-UHFFFAOYSA-N 2-amino-2-(3-chloro-4-fluorophenyl)ethanol Chemical compound OCC(N)C1=CC=C(F)C(Cl)=C1 CYZCJADBZVABTN-UHFFFAOYSA-N 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- QNQUBGPYUVRMSB-SECBINFHSA-N (1r)-1-(4-chloro-3-fluorophenyl)propan-1-amine Chemical compound CC[C@@H](N)C1=CC=C(Cl)C(F)=C1 QNQUBGPYUVRMSB-SECBINFHSA-N 0.000 claims description 5
- MIFMZIPFCNEFBM-SECBINFHSA-N (1r)-1-[4-(difluoromethoxy)phenyl]propan-1-amine Chemical compound CC[C@@H](N)C1=CC=C(OC(F)F)C=C1 MIFMZIPFCNEFBM-SECBINFHSA-N 0.000 claims description 5
- YTHACPLZDAHPTP-MRVPVSSYSA-N (2s)-2-amino-2-[4-(difluoromethoxy)phenyl]ethanol Chemical compound OC[C@@H](N)C1=CC=C(OC(F)F)C=C1 YTHACPLZDAHPTP-MRVPVSSYSA-N 0.000 claims description 5
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 5
- NNZNDGFJDKAJLG-UHFFFAOYSA-N 1h-2,6-naphthyridine-2-carboxylic acid Chemical compound C1=NC=C2C=CN(C(=O)O)CC2=C1 NNZNDGFJDKAJLG-UHFFFAOYSA-N 0.000 claims description 5
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 5
- BLNCONOUQXEUCP-UHFFFAOYSA-N 2-amino-2-(4-chloro-3-fluorophenyl)ethanol Chemical compound OCC(N)C1=CC=C(Cl)C(F)=C1 BLNCONOUQXEUCP-UHFFFAOYSA-N 0.000 claims description 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- FFQSFXAOMSUUCV-SECBINFHSA-N (1R)-1-(3-fluoro-4-methoxyphenyl)propan-1-amine Chemical compound CC[C@@H](N)C1=CC=C(OC)C(F)=C1 FFQSFXAOMSUUCV-SECBINFHSA-N 0.000 claims description 4
- FCOAUPWCOYGMFE-MRVPVSSYSA-N (1R)-1-[3-fluoro-4-(trifluoromethoxy)phenyl]propan-1-amine Chemical compound CC[C@@H](N)c1ccc(OC(F)(F)F)c(F)c1 FCOAUPWCOYGMFE-MRVPVSSYSA-N 0.000 claims description 4
- BVVJDCFVSXSRBB-RXMQYKEDSA-N (1r)-1-(3-chloro-5-fluorophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC(F)=CC(Cl)=C1 BVVJDCFVSXSRBB-RXMQYKEDSA-N 0.000 claims description 4
- SRVZZCBLNXFARS-RXMQYKEDSA-N (1r)-1-(4-chloro-3-fluorophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=C(Cl)C(F)=C1 SRVZZCBLNXFARS-RXMQYKEDSA-N 0.000 claims description 4
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- VBWRNUHVGFPJRG-SECBINFHSA-N (1r)-1-(3,4-dichlorophenyl)propan-1-amine Chemical compound CC[C@@H](N)C1=CC=C(Cl)C(Cl)=C1 VBWRNUHVGFPJRG-SECBINFHSA-N 0.000 claims description 3
- QGCLEUGNYRXBMZ-ZCFIWIBFSA-N (1r)-1-(4-fluorophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=C(F)C=C1 QGCLEUGNYRXBMZ-ZCFIWIBFSA-N 0.000 claims description 3
- KZXMHEBPONONDK-OIBJUYFYSA-N (3S,4R)-4-(4-chloro-3-fluorophenyl)pyrrolidin-3-amine Chemical compound N[C@@H]1CNC[C@H]1C1=CC=C(Cl)C(F)=C1 KZXMHEBPONONDK-OIBJUYFYSA-N 0.000 claims description 3
- JCGNJHHXMLDXRC-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)propane-1,3-diamine Chemical compound NCCC(N)C1=CC=C(Cl)C(Cl)=C1 JCGNJHHXMLDXRC-UHFFFAOYSA-N 0.000 claims description 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- DSHGWXMIUPNWEP-CYBMUJFWSA-N C1([C@@H](C)NC(=O)N2CCC3=CN=C(N=C3C2)NC(C)C)=CC=C(F)C=C1 Chemical compound C1([C@@H](C)NC(=O)N2CCC3=CN=C(N=C3C2)NC(C)C)=CC=C(F)C=C1 DSHGWXMIUPNWEP-CYBMUJFWSA-N 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 208000008930 Low Back Pain Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- HVAKTAOFRQKFME-SNVBAGLBSA-N (1R)-1-[4-(2,2,2-trifluoroethoxy)phenyl]propan-1-amine Chemical compound CC[C@@H](N)C1=CC=C(OCC(F)(F)F)C=C1 HVAKTAOFRQKFME-SNVBAGLBSA-N 0.000 claims description 2
- QHARBBFZGIDKLK-RXMQYKEDSA-N (1r)-1-(3-chloro-4-fluorophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=C(F)C(Cl)=C1 QHARBBFZGIDKLK-RXMQYKEDSA-N 0.000 claims description 2
- BWZFVQWUKNCKQL-SECBINFHSA-N (1r)-1-(4-fluorophenyl)propan-1-amine Chemical compound CC[C@@H](N)C1=CC=C(F)C=C1 BWZFVQWUKNCKQL-SECBINFHSA-N 0.000 claims description 2
- MIFMZIPFCNEFBM-VIFPVBQESA-N (1s)-1-[4-(difluoromethoxy)phenyl]propan-1-amine Chemical compound CC[C@H](N)C1=CC=C(OC(F)F)C=C1 MIFMZIPFCNEFBM-VIFPVBQESA-N 0.000 claims description 2
- CTBPDZHZGYKVRA-UHFFFAOYSA-N (4-chloro-3-fluorophenyl)-(1,3-oxazol-5-yl)methanamine Chemical compound C=1C=C(Cl)C(F)=CC=1C(N)C1=CN=CO1 CTBPDZHZGYKVRA-UHFFFAOYSA-N 0.000 claims description 2
- JLXWGARTNXOMLA-SNVBAGLBSA-N (R)-(4-chloro-3-fluorophenyl)-(1,3-oxazol-4-yl)methanamine Chemical compound C1([C@H](N)C=2C=C(F)C(Cl)=CC=2)=COC=N1 JLXWGARTNXOMLA-SNVBAGLBSA-N 0.000 claims description 2
- UGTQLRZGDVYBRH-LLVKDONJSA-N (R)-(4-chloro-3-fluorophenyl)-(1-methylpyrazol-4-yl)methanamine Chemical compound Cn1cc(cn1)[C@H](N)c1ccc(Cl)c(F)c1 UGTQLRZGDVYBRH-LLVKDONJSA-N 0.000 claims description 2
- JLXWGARTNXOMLA-JTQLQIEISA-N (S)-(4-chloro-3-fluorophenyl)-(1,3-oxazol-4-yl)methanamine Chemical compound C1([C@@H](N)C=2C=C(F)C(Cl)=CC=2)=COC=N1 JLXWGARTNXOMLA-JTQLQIEISA-N 0.000 claims description 2
- BYXLFFDKBZRBOD-ZDUSSCGKSA-N (S)-[3-fluoro-4-(trifluoromethyl)phenyl]-(6-methoxypyridin-2-yl)methanamine Chemical compound COc1cccc(n1)[C@@H](N)c1ccc(c(F)c1)C(F)(F)F BYXLFFDKBZRBOD-ZDUSSCGKSA-N 0.000 claims description 2
- UGTQLRZGDVYBRH-NSHDSACASA-N (s)-(4-chloro-3-fluorophenyl)-(1-methylpyrazol-4-yl)methanamine Chemical compound C1=NN(C)C=C1[C@@H](N)C1=CC=C(Cl)C(F)=C1 UGTQLRZGDVYBRH-NSHDSACASA-N 0.000 claims description 2
- RFWDQVNFSXQMMI-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-3,3,3-trifluoropropan-1-amine Chemical compound FC(F)(F)CC(N)C1=CC=C(Cl)C(Cl)=C1 RFWDQVNFSXQMMI-UHFFFAOYSA-N 0.000 claims description 2
- UCOSRTUSVXHIMK-UHFFFAOYSA-N 1h-benzimidazol-2-ylmethanamine Chemical compound C1=CC=C2NC(CN)=NC2=C1 UCOSRTUSVXHIMK-UHFFFAOYSA-N 0.000 claims description 2
- QWSYXQMUSXKUCN-OAHLLOKOSA-N 2-(oxan-4-ylamino)-N-[(1R)-1-phenylethyl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound N([C@H](C)C=1C=CC=CC=1)C(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 QWSYXQMUSXKUCN-OAHLLOKOSA-N 0.000 claims description 2
- ZRKJGGGKZXIGPE-UHFFFAOYSA-N 3-[1-[2-(oxan-4-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carbonyl]pyrrolidin-2-yl]benzonitrile Chemical compound C1CC2=CN=C(NC3CCOCC3)N=C2CN1C(=O)N1CCCC1C1=CC=CC(C#N)=C1 ZRKJGGGKZXIGPE-UHFFFAOYSA-N 0.000 claims description 2
- MIYUHKALQKBPEW-UHFFFAOYSA-N 4-(aminomethyl)-2-chlorobenzonitrile Chemical compound NCC1=CC=C(C#N)C(Cl)=C1 MIYUHKALQKBPEW-UHFFFAOYSA-N 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000003200 Adenoma Diseases 0.000 claims description 2
- 206010001233 Adenoma benign Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- WDGWUYWMHYOHHV-UHFFFAOYSA-N C1=C(C#N)C(C(F)(F)F)=CC(CNC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)=C1 Chemical compound C1=C(C#N)C(C(F)(F)F)=CC(CNC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)=C1 WDGWUYWMHYOHHV-UHFFFAOYSA-N 0.000 claims description 2
- AQIGVFKWPOBIMP-UHFFFAOYSA-N C1=C2C=CNC2=CC(CNC(=O)N2CCC3=CN=C(N=C3C2)NC(C)C)=C1 Chemical compound C1=C2C=CNC2=CC(CNC(=O)N2CCC3=CN=C(N=C3C2)NC(C)C)=C1 AQIGVFKWPOBIMP-UHFFFAOYSA-N 0.000 claims description 2
- OQOQVAUAXIAFML-ZDUSSCGKSA-N C1=C2C=CNC2=CC(CNC(=O)N2CCC3=CN=C(N=C3C2)N[C@H](CO)C)=C1 Chemical compound C1=C2C=CNC2=CC(CNC(=O)N2CCC3=CN=C(N=C3C2)N[C@H](CO)C)=C1 OQOQVAUAXIAFML-ZDUSSCGKSA-N 0.000 claims description 2
- BKDCLHLEVFMDIO-UHFFFAOYSA-N C1=CC=C2NC(CNC(=O)N3CCC4=CN=C(N=C4C3)NC(C)C)=CC2=C1 Chemical compound C1=CC=C2NC(CNC(=O)N3CCC4=CN=C(N=C4C3)NC(C)C)=CC2=C1 BKDCLHLEVFMDIO-UHFFFAOYSA-N 0.000 claims description 2
- VPZHKHWCTDGGGJ-LBPRGKRZSA-N C1=CC=C2OC(CNC(=O)N3CCC4=CN=C(N=C4C3)N[C@H](CO)C)=NC2=C1 Chemical compound C1=CC=C2OC(CNC(=O)N3CCC4=CN=C(N=C4C3)N[C@H](CO)C)=NC2=C1 VPZHKHWCTDGGGJ-LBPRGKRZSA-N 0.000 claims description 2
- SSVCOSGPUVSWRA-UHFFFAOYSA-N C1=CC=C2SC(C(C)NC(=O)N3CCC4=CN=C(N=C4C3)NC(C)C)=NC2=C1 Chemical compound C1=CC=C2SC(C(C)NC(=O)N3CCC4=CN=C(N=C4C3)NC(C)C)=NC2=C1 SSVCOSGPUVSWRA-UHFFFAOYSA-N 0.000 claims description 2
- LPJWPHYIVPUWCV-UHFFFAOYSA-N C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NC(C=1C=C(Cl)C(Cl)=CC=1)C1=CC=NN1 Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NC(C=1C=C(Cl)C(Cl)=CC=1)C1=CC=NN1 LPJWPHYIVPUWCV-UHFFFAOYSA-N 0.000 claims description 2
- NQEZAQZKJLKXJC-UHFFFAOYSA-N C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NC1(C=2C=C(Cl)C(Cl)=CC=2)CCN(C)CC1 Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NC1(C=2C=C(Cl)C(Cl)=CC=2)CCN(C)CC1 NQEZAQZKJLKXJC-UHFFFAOYSA-N 0.000 claims description 2
- PSSQRZLKLOZCQR-UHFFFAOYSA-N C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NC1(C=2C=CC=CC=2)CCNCC1 Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NC1(C=2C=CC=CC=2)CCNCC1 PSSQRZLKLOZCQR-UHFFFAOYSA-N 0.000 claims description 2
- RIXRPATTXPFLHS-ZDUSSCGKSA-N C1C2=NC(N[C@H](CO)C)=NC=C2CCN1C(=O)NCC1=CC=CC2=C1NC=C2 Chemical compound C1C2=NC(N[C@H](CO)C)=NC=C2CCN1C(=O)NCC1=CC=CC2=C1NC=C2 RIXRPATTXPFLHS-ZDUSSCGKSA-N 0.000 claims description 2
- HKMRFTJYOBAVDS-UHFFFAOYSA-N C=1C2=CC(F)=CC=C2NC=1CNC(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 Chemical compound C=1C2=CC(F)=CC=C2NC=1CNC(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 HKMRFTJYOBAVDS-UHFFFAOYSA-N 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- UPBKNGNPEYNTKB-UHFFFAOYSA-N FC1=CC=C2NC(CNC(=O)N3CCC4=CN=C(N=C4C3)NC(C)C)=CC2=C1 Chemical compound FC1=CC=C2NC(CNC(=O)N3CCC4=CN=C(N=C4C3)NC(C)C)=CC2=C1 UPBKNGNPEYNTKB-UHFFFAOYSA-N 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 206010023347 Keratoacanthoma Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims description 2
- UFSDGAZHBNVBFN-NSHDSACASA-N N-[(3,4-dichlorophenyl)methyl]-2-[[(2S)-1-hydroxypropan-2-yl]amino]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1C2=NC(N[C@H](CO)C)=NC=C2CCN1C(=O)NCC1=CC=C(Cl)C(Cl)=C1 UFSDGAZHBNVBFN-NSHDSACASA-N 0.000 claims description 2
- CRECTGDAJHCVGJ-UHFFFAOYSA-N N-[3-(4-chlorophenyl)pyrrolidin-3-yl]-2-(4-fluoroanilino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1=CC(F)=CC=C1NC1=NC=C(CCN(C2)C(=O)NC3(CNCC3)C=3C=CC(Cl)=CC=3)C2=N1 CRECTGDAJHCVGJ-UHFFFAOYSA-N 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- NUQJREOZCWPXCP-UHFFFAOYSA-N [2-(oxan-4-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-(2-pyridin-2-ylpyrrolidin-1-yl)methanone Chemical compound C1CC2=CN=C(NC3CCOCC3)N=C2CN1C(=O)N1CCCC1C1=CC=CC=N1 NUQJREOZCWPXCP-UHFFFAOYSA-N 0.000 claims description 2
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- VYMKNKSTAQBRPC-QGZVFWFLSA-N n-[(1s)-1-(3,4-dichlorophenyl)-2-hydroxyethyl]-2-(propan-2-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1([C@@H](CO)NC(=O)N2CCC3=CN=C(N=C3C2)NC(C)C)=CC=C(Cl)C(Cl)=C1 VYMKNKSTAQBRPC-QGZVFWFLSA-N 0.000 claims description 2
- LAOUBXGHNQWXMB-UHFFFAOYSA-N n-[1-(1,3-benzothiazol-2-yl)ethyl]-2-(4-fluoroanilino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound N=1C2=CC=CC=C2SC=1C(C)NC(=O)N(CC1=N2)CCC1=CN=C2NC1=CC=C(F)C=C1 LAOUBXGHNQWXMB-UHFFFAOYSA-N 0.000 claims description 2
- IVRKWYFZHFNRSH-UHFFFAOYSA-N n-methyl-2-(oxan-4-ylamino)-n-(1-phenylethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C=1C=CC=CC=1C(C)N(C)C(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 IVRKWYFZHFNRSH-UHFFFAOYSA-N 0.000 claims description 2
- 201000010198 papillary carcinoma Diseases 0.000 claims description 2
- 201000003068 rheumatic fever Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000000649 small cell carcinoma Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims description 2
- 208000010576 undifferentiated carcinoma Diseases 0.000 claims description 2
- PEFZYDMBDWLDOR-ZETCQYMHSA-N 2-[[(2s)-1-hydroxypropan-2-yl]amino]-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxylic acid Chemical compound C1CN(C(O)=O)CC2=NC(N[C@H](CO)C)=NC=C21 PEFZYDMBDWLDOR-ZETCQYMHSA-N 0.000 claims 5
- RTONQWDNXXURRA-UHFFFAOYSA-N 6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxylic acid Chemical compound N1=CN=C2CN(C(=O)O)CCC2=C1 RTONQWDNXXURRA-UHFFFAOYSA-N 0.000 claims 4
- LXYGOSJYDNZVTO-MRVPVSSYSA-N (2s)-2-amino-2-(3,4-dichlorophenyl)ethanol Chemical compound OC[C@@H](N)C1=CC=C(Cl)C(Cl)=C1 LXYGOSJYDNZVTO-MRVPVSSYSA-N 0.000 claims 3
- WVBWKBCYZYKZMY-UHFFFAOYSA-N 2-(oxan-4-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxylic acid Chemical compound N1=C2CN(C(=O)O)CCC2=CN=C1NC1CCOCC1 WVBWKBCYZYKZMY-UHFFFAOYSA-N 0.000 claims 3
- AUJUTMYDMJPCLB-QWRGUYRKSA-N (S)-(3,4-dichlorophenyl)-[(2S)-pyrrolidin-2-yl]methanamine Chemical compound N[C@H]([C@@H]1CCCN1)c1ccc(Cl)c(Cl)c1 AUJUTMYDMJPCLB-QWRGUYRKSA-N 0.000 claims 2
- LJARTIRDTGSOGS-UHFFFAOYSA-N 1-[2-(oxan-4-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-2-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]ethanone Chemical compound C1=CC(C(F)(F)F)=CC=C1C1N(CC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)CCC1 LJARTIRDTGSOGS-UHFFFAOYSA-N 0.000 claims 2
- NTQOAJKTVWUCQG-UHFFFAOYSA-N 2-(4-methyl-2-phenylpiperazin-1-yl)-1-[2-(oxan-4-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]ethanone Chemical compound C=1C=CC=CC=1C1CN(C)CCN1CC(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 NTQOAJKTVWUCQG-UHFFFAOYSA-N 0.000 claims 2
- YBQDDJHHAHQECL-UHFFFAOYSA-N 2-(propan-2-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxylic acid Chemical compound C1CN(C(O)=O)CC2=NC(NC(C)C)=NC=C21 YBQDDJHHAHQECL-UHFFFAOYSA-N 0.000 claims 2
- ZDURYKHOVINXHX-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)piperidin-1-yl]-1-[2-(oxan-4-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]ethanone Chemical compound C1=CC(F)=CC=C1C1N(CC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)CCCC1 ZDURYKHOVINXHX-UHFFFAOYSA-N 0.000 claims 2
- LKSSLRMWTCCEOU-SNVBAGLBSA-N (1R)-1-(3,4-dichlorophenyl)-3-methylsulfonylpropan-1-amine Chemical compound CS(=O)(=O)CC[C@@H](N)C1=CC=C(Cl)C(Cl)=C1 LKSSLRMWTCCEOU-SNVBAGLBSA-N 0.000 claims 1
- PMULIJSEULAHHT-SECBINFHSA-N (1R)-1-(3-chloro-4-methoxyphenyl)propan-1-amine Chemical compound CC[C@@H](N)C1=CC=C(OC)C(Cl)=C1 PMULIJSEULAHHT-SECBINFHSA-N 0.000 claims 1
- VIDPJIAQADUIJC-SCSAIBSYSA-N (1R)-1-(4-chloro-2,5-difluorophenyl)ethanamine Chemical compound C[C@@H](N)c1cc(F)c(Cl)cc1F VIDPJIAQADUIJC-SCSAIBSYSA-N 0.000 claims 1
- MHGOLEQBUMUCJZ-ZWNOBZJWSA-N (1R)-1-(4-chloro-3-fluorophenyl)-2-[(2R)-piperidin-2-yl]ethanamine Chemical compound N[C@H](C[C@H]1CCCCN1)c1ccc(Cl)c(F)c1 MHGOLEQBUMUCJZ-ZWNOBZJWSA-N 0.000 claims 1
- KASAIQGUILVRIE-SECBINFHSA-N (1S)-1-(3-chloro-4-fluorophenyl)-N'-methylethane-1,2-diamine Chemical compound CNC[C@@H](N)C1=CC=C(F)C(Cl)=C1 KASAIQGUILVRIE-SECBINFHSA-N 0.000 claims 1
- DRFISBLBMPKEFM-SECBINFHSA-N (1S)-1-[3-fluoro-4-(trifluoromethyl)phenyl]-2-methoxyethanamine Chemical compound COC[C@@H](N)C1=CC=C(C(F)(F)F)C(F)=C1 DRFISBLBMPKEFM-SECBINFHSA-N 0.000 claims 1
- OUVZHZAOWDHBOU-RXMQYKEDSA-N (1r)-1-(2,4-dichlorophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=C(Cl)C=C1Cl OUVZHZAOWDHBOU-RXMQYKEDSA-N 0.000 claims 1
- QWYPAKQHZBBLFE-SCSAIBSYSA-N (1r)-1-(3,4,5-trifluorophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC(F)=C(F)C(F)=C1 QWYPAKQHZBBLFE-SCSAIBSYSA-N 0.000 claims 1
- AESHLRAPTJZOJL-RXMQYKEDSA-N (1r)-1-(3,4-difluorophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=C(F)C(F)=C1 AESHLRAPTJZOJL-RXMQYKEDSA-N 0.000 claims 1
- LWTZLRLBBSSNEN-SECBINFHSA-N (1r)-1-(3,4-difluorophenyl)propan-1-amine Chemical compound CC[C@@H](N)C1=CC=C(F)C(F)=C1 LWTZLRLBBSSNEN-SECBINFHSA-N 0.000 claims 1
- GUMZDWPMXGQNBG-ZCFIWIBFSA-N (1r)-1-[4-(trifluoromethyl)phenyl]ethanamine Chemical compound C[C@@H](N)C1=CC=C(C(F)(F)F)C=C1 GUMZDWPMXGQNBG-ZCFIWIBFSA-N 0.000 claims 1
- YOETTZCHIABKPH-SECBINFHSA-N (1r)-1-[4-(trifluoromethyl)phenyl]propan-1-amine Chemical compound CC[C@@H](N)C1=CC=C(C(F)(F)F)C=C1 YOETTZCHIABKPH-SECBINFHSA-N 0.000 claims 1
- PXRKLPWAUIYHBN-SECBINFHSA-N (1s)-1-(3,4-dichlorophenyl)-2-methoxyethanamine Chemical compound COC[C@@H](N)C1=CC=C(Cl)C(Cl)=C1 PXRKLPWAUIYHBN-SECBINFHSA-N 0.000 claims 1
- QGCLEUGNYRXBMZ-LURJTMIESA-N (1s)-1-(4-fluorophenyl)ethanamine Chemical compound C[C@H](N)C1=CC=C(F)C=C1 QGCLEUGNYRXBMZ-LURJTMIESA-N 0.000 claims 1
- JHBVZGONNIVXFJ-UHFFFAOYSA-N (2,3-dichlorophenyl)methanamine Chemical compound NCC1=CC=CC(Cl)=C1Cl JHBVZGONNIVXFJ-UHFFFAOYSA-N 0.000 claims 1
- SJUKJZSTBBSGHF-UHFFFAOYSA-N (2,4-dichlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1Cl SJUKJZSTBBSGHF-UHFFFAOYSA-N 0.000 claims 1
- ASKCJSKAUHXGFS-UHFFFAOYSA-N (2-benzylpyrrolidin-1-yl)-[2-(oxan-4-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]methanone Chemical compound C1CC2=CN=C(NC3CCOCC3)N=C2CN1C(=O)N1CCCC1CC1=CC=CC=C1 ASKCJSKAUHXGFS-UHFFFAOYSA-N 0.000 claims 1
- IYNLFXHJQWYZOH-VIFPVBQESA-N (3S)-3-amino-3-[3-fluoro-4-(trifluoromethyl)phenyl]propan-1-ol Chemical compound OCC[C@H](N)C1=CC=C(C(F)(F)F)C(F)=C1 IYNLFXHJQWYZOH-VIFPVBQESA-N 0.000 claims 1
- GEWZQMLZRVNCHB-MRXNPFEDSA-N (3S)-4-amino-3-(4-chlorophenyl)-1-[2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]butan-1-one Chemical compound C1([C@@H](CN)CC(=O)N2CCC3=CN=C(N=C3C2)NC(C)C)=CC=C(Cl)C=C1 GEWZQMLZRVNCHB-MRXNPFEDSA-N 0.000 claims 1
- MNHGOSBXFWTLKG-OIBJUYFYSA-N (3S,4R)-4-(3,4-difluorophenyl)pyrrolidin-3-amine Chemical compound N[C@@H]1CNC[C@H]1C1=CC=C(F)C(F)=C1 MNHGOSBXFWTLKG-OIBJUYFYSA-N 0.000 claims 1
- ZEDYZSQWQRJBFO-QGZVFWFLSA-N (3s)-3-(4-chlorophenyl)-4-(methylamino)-1-[2-(propan-2-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]butan-1-one Chemical compound C1([C@H](CC(=O)N2CC3=NC(NC(C)C)=NC=C3CC2)CNC)=CC=C(Cl)C=C1 ZEDYZSQWQRJBFO-QGZVFWFLSA-N 0.000 claims 1
- LTLMCCREECKIAJ-GZMMTYOYSA-N (3s,4r)-4-(4-chloro-3-fluorophenyl)-1-methylpyrrolidin-3-amine Chemical compound C1N(C)C[C@@H](N)[C@@H]1C1=CC=C(Cl)C(F)=C1 LTLMCCREECKIAJ-GZMMTYOYSA-N 0.000 claims 1
- ODMMHGMIZYLHNN-UHFFFAOYSA-N (4-chloro-2-fluorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1F ODMMHGMIZYLHNN-UHFFFAOYSA-N 0.000 claims 1
- HSNPBYKCCNMQNA-UHFFFAOYSA-N (4-chloro-3-fluorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C(F)=C1 HSNPBYKCCNMQNA-UHFFFAOYSA-N 0.000 claims 1
- WAKQNVBXOVKCGH-LLVKDONJSA-N (R)-(4-chloro-3-fluorophenyl)-(1-methylpyrazol-3-yl)methanamine Chemical compound CN1C=CC([C@H](N)C=2C=C(F)C(Cl)=CC=2)=N1 WAKQNVBXOVKCGH-LLVKDONJSA-N 0.000 claims 1
- QWAPKTKNAAUWQX-NSHDSACASA-N (S)-(3-chloro-4-fluorophenyl)-(1-methylpyrazol-4-yl)methanamine Chemical compound C1=NN(C)C=C1[C@@H](N)C1=CC=C(F)C(Cl)=C1 QWAPKTKNAAUWQX-NSHDSACASA-N 0.000 claims 1
- NAPXKJJCNWXOIL-LBPRGKRZSA-N (S)-(3-chloro-4-methoxyphenyl)-(1-methylpyrazol-4-yl)methanamine Chemical compound C1=C(Cl)C(OC)=CC=C1[C@H](N)C1=CN(C)N=C1 NAPXKJJCNWXOIL-LBPRGKRZSA-N 0.000 claims 1
- FZSAQVHGCSNHRL-QWRGUYRKSA-N (S)-[3-fluoro-4-(trifluoromethyl)phenyl]-[(2S)-pyrrolidin-2-yl]methanamine Chemical compound N[C@H]([C@@H]1CCCN1)c1ccc(c(F)c1)C(F)(F)F FZSAQVHGCSNHRL-QWRGUYRKSA-N 0.000 claims 1
- IQTYZCNZSRKYKS-NEPJUHHUSA-N (s)-(3,4-dichlorophenyl)-[(2r)-1-methylpyrrolidin-2-yl]methanamine Chemical compound CN1CCC[C@@H]1[C@@H](N)C1=CC=C(Cl)C(Cl)=C1 IQTYZCNZSRKYKS-NEPJUHHUSA-N 0.000 claims 1
- WAKQNVBXOVKCGH-NSHDSACASA-N (s)-(4-chloro-3-fluorophenyl)-(1-methylpyrazol-3-yl)methanamine Chemical compound CN1C=CC([C@@H](N)C=2C=C(F)C(Cl)=CC=2)=N1 WAKQNVBXOVKCGH-NSHDSACASA-N 0.000 claims 1
- LOKDJYRQJIHDLQ-NSHDSACASA-N (s)-(4-chloro-3-fluorophenyl)-(2-methylpyrazol-3-yl)methanamine Chemical compound CN1N=CC=C1[C@@H](N)C1=CC=C(Cl)C(F)=C1 LOKDJYRQJIHDLQ-NSHDSACASA-N 0.000 claims 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 claims 1
- MMODQIOMTUFSBM-UHFFFAOYSA-N 1-[2-(1-hydroxypropan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-3-[4-(trifluoromethyl)phenyl]butan-1-one Chemical compound C1C2=NC(NC(CO)C)=NC=C2CCN1C(=O)CC(C)C1=CC=C(C(F)(F)F)C=C1 MMODQIOMTUFSBM-UHFFFAOYSA-N 0.000 claims 1
- RUVYTRNNSDOVLI-QFIPXVFZSA-N 1-[2-(oxan-4-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-2-[(3R)-3-phenylmorpholin-4-yl]ethanone Chemical compound C1([C@@H]2COCCN2CC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)=CC=CC=C1 RUVYTRNNSDOVLI-QFIPXVFZSA-N 0.000 claims 1
- RUVYTRNNSDOVLI-JOCHJYFZSA-N 1-[2-(oxan-4-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-2-[(3S)-3-phenylmorpholin-4-yl]ethanone Chemical compound C1([C@H]2COCCN2CC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)=CC=CC=C1 RUVYTRNNSDOVLI-JOCHJYFZSA-N 0.000 claims 1
- QDTFEDDOIGKXEM-UHFFFAOYSA-N 1-[2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-3-[4-(trifluoromethyl)phenyl]butan-1-one Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)CC(C)C1=CC=C(C(F)(F)F)C=C1 QDTFEDDOIGKXEM-UHFFFAOYSA-N 0.000 claims 1
- FDKWRGJBTPPFJO-UHFFFAOYSA-N 1-phenyl-n-(trifluoromethylsulfanyl)methanamine Chemical compound FC(F)(F)SNCC1=CC=CC=C1 FDKWRGJBTPPFJO-UHFFFAOYSA-N 0.000 claims 1
- VVDSVZNHMCJOHE-UHFFFAOYSA-N 2-(1-hydroxypropan-2-ylamino)-N-(2-phenylcyclopropyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1C2=NC(NC(CO)C)=NC=C2CCN1C(=O)NC1CC1C1=CC=CC=C1 VVDSVZNHMCJOHE-UHFFFAOYSA-N 0.000 claims 1
- HBTDFZYBFUTDRP-UHFFFAOYSA-N 2-(benzylamino)-2-methylpropanenitrile Chemical compound N#CC(C)(C)NCC1=CC=CC=C1 HBTDFZYBFUTDRP-UHFFFAOYSA-N 0.000 claims 1
- JYQVCRVCOMGMEX-UHFFFAOYSA-N 2-(oxan-4-ylamino)-N-[[4-(trifluoromethyl)phenyl]methyl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)N1CC2=NC(NC3CCOCC3)=NC=C2CC1 JYQVCRVCOMGMEX-UHFFFAOYSA-N 0.000 claims 1
- GHOISFSTGPGMNN-UHFFFAOYSA-N 2-(propan-2-ylamino)-N-[4-[4-(trifluoromethyl)phenyl]pyrrolidin-3-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NC1CNCC1C1=CC=C(C(F)(F)F)C=C1 GHOISFSTGPGMNN-UHFFFAOYSA-N 0.000 claims 1
- XKMMZHZRODHFGH-UHFFFAOYSA-N 2-[2-(4-chlorophenyl)piperazin-1-yl]-1-[2-(oxan-4-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]ethanone Chemical compound C1=CC(Cl)=CC=C1C1N(CC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)CCNC1 XKMMZHZRODHFGH-UHFFFAOYSA-N 0.000 claims 1
- ROEQONSZGMXAKE-UHFFFAOYSA-N 2-[3-chloro-4-fluoro-N-(2-hydroxyethyl)anilino]-1-[2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]ethanone Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)CN(CCO)C1=CC=C(F)C(Cl)=C1 ROEQONSZGMXAKE-UHFFFAOYSA-N 0.000 claims 1
- LXYGOSJYDNZVTO-UHFFFAOYSA-N 2-amino-2-(3,4-dichlorophenyl)ethanol Chemical compound OCC(N)C1=CC=C(Cl)C(Cl)=C1 LXYGOSJYDNZVTO-UHFFFAOYSA-N 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- KSCDIOLFKBWQRJ-UHFFFAOYSA-N 3-(2,4-dichlorophenyl)-1-[2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]propan-1-one Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)CCC1=CC=C(Cl)C=C1Cl KSCDIOLFKBWQRJ-UHFFFAOYSA-N 0.000 claims 1
- SQHJOZTWSLWYAG-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-1-[2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]propan-1-one Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)CCC1=CC=C(Cl)C(Cl)=C1 SQHJOZTWSLWYAG-UHFFFAOYSA-N 0.000 claims 1
- SSXRTJANNGHJTL-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-1-[2-[(3-hydroxycyclopentyl)amino]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]butan-1-one Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C)CC(=O)N(CC1=N2)CCC1=CN=C2NC1CCC(O)C1 SSXRTJANNGHJTL-UHFFFAOYSA-N 0.000 claims 1
- ZPKUDZMJCZUFNY-UHFFFAOYSA-N 3-(3,4-difluorophenyl)-1-[2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]propan-1-one Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)CCC1=CC=C(F)C(F)=C1 ZPKUDZMJCZUFNY-UHFFFAOYSA-N 0.000 claims 1
- KGBDIWCPVGUTAG-UHFFFAOYSA-N 3-(3-chloro-4-fluorophenyl)-4-hydroxy-1-[2-(propan-2-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]butan-1-one Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)CC(CO)C1=CC=C(F)C(Cl)=C1 KGBDIWCPVGUTAG-UHFFFAOYSA-N 0.000 claims 1
- DZEQMYUIFDUOIM-UHFFFAOYSA-N 3-(3-fluorophenyl)-1-[2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]propan-1-one Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)CCC1=CC=CC(F)=C1 DZEQMYUIFDUOIM-UHFFFAOYSA-N 0.000 claims 1
- ZKDCVVBYQWQNHB-UHFFFAOYSA-N 3-(4-chloro-2-fluorophenyl)-1-[2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]propan-1-one Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)CCC1=CC=C(Cl)C=C1F ZKDCVVBYQWQNHB-UHFFFAOYSA-N 0.000 claims 1
- NSIZLXRHHBZUTI-UHFFFAOYSA-N 3-(4-fluorophenyl)-1-[2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]propan-1-one Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)CCC1=CC=C(F)C=C1 NSIZLXRHHBZUTI-UHFFFAOYSA-N 0.000 claims 1
- XFKPORAVEUOIRF-UHFFFAOYSA-N 3-(aminomethyl)benzonitrile Chemical compound NCC1=CC=CC(C#N)=C1 XFKPORAVEUOIRF-UHFFFAOYSA-N 0.000 claims 1
- QWXPJQOMDJZOJD-UHFFFAOYSA-N 3-[3-fluoro-4-(trifluoromethyl)phenyl]-1-[2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]hexan-1-one Chemical compound C1CC2=CN=C(NC(C)C)N=C2CN1C(=O)CC(CCC)C1=CC=C(C(F)(F)F)C(F)=C1 QWXPJQOMDJZOJD-UHFFFAOYSA-N 0.000 claims 1
- CFNAMLAVUTUGPM-UHFFFAOYSA-N 3-amino-3-(3,4-dichlorophenyl)propan-1-ol Chemical compound OCCC(N)C1=CC=C(Cl)C(Cl)=C1 CFNAMLAVUTUGPM-UHFFFAOYSA-N 0.000 claims 1
- IYNLFXHJQWYZOH-UHFFFAOYSA-N 3-amino-3-[3-fluoro-4-(trifluoromethyl)phenyl]propan-1-ol Chemical compound OCCC(N)C1=CC=C(C(F)(F)F)C(F)=C1 IYNLFXHJQWYZOH-UHFFFAOYSA-N 0.000 claims 1
- RSSZQIZCDMEBKX-SNVBAGLBSA-N 4-[(1R)-1-aminopropyl]-2-chlorobenzonitrile Chemical compound CC[C@@H](N)C1=CC=C(C#N)C(Cl)=C1 RSSZQIZCDMEBKX-SNVBAGLBSA-N 0.000 claims 1
- YHTVICMOTRTRTD-GFCCVEGCSA-N 4-[(R)-amino-(1-methylpyrazol-4-yl)methyl]-2-chlorobenzonitrile Chemical compound Cn1cc(cn1)[C@H](N)c1ccc(C#N)c(Cl)c1 YHTVICMOTRTRTD-GFCCVEGCSA-N 0.000 claims 1
- JUOQLJRCLUFOTM-UHFFFAOYSA-N 4-amino-3-(3-chloro-4-fluorophenyl)-1-[2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]butan-1-one Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)CC(CN)C1=CC=C(F)C(Cl)=C1 JUOQLJRCLUFOTM-UHFFFAOYSA-N 0.000 claims 1
- SGWFLRZPZVDLRV-UHFFFAOYSA-N 4-amino-3-(4-chloro-3-fluorophenyl)-1-[2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]butan-1-one Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)CC(CN)C1=CC=C(Cl)C(F)=C1 SGWFLRZPZVDLRV-UHFFFAOYSA-N 0.000 claims 1
- MQKHBYBZXRMIRG-UHFFFAOYSA-N 7-(propan-2-ylamino)-N-[4-[4-(trifluoromethyl)phenyl]pyrrolidin-3-yl]-3,4-dihydro-1H-2,6-naphthyridine-2-carboxamide Chemical compound C1CC=2C=NC(NC(C)C)=CC=2CN1C(=O)NC1CNCC1C1=CC=C(C(F)(F)F)C=C1 MQKHBYBZXRMIRG-UHFFFAOYSA-N 0.000 claims 1
- YWQQXBKNIVXLMR-HNNXBMFYSA-N C([C@@H](CO)NC(=O)N1CCC2=CN=C(N=C2C1)NC(C)C)C1=CC=C(Cl)C(Cl)=C1 Chemical compound C([C@@H](CO)NC(=O)N1CCC2=CN=C(N=C2C1)NC(C)C)C1=CC=C(Cl)C(Cl)=C1 YWQQXBKNIVXLMR-HNNXBMFYSA-N 0.000 claims 1
- XLRDAQUUPXAIIS-KRWDZBQOSA-N C([C@@H](CO)NC(=O)N1CCC2=CN=C(N=C2C1)NC(C)C)C1=CC=C(Cl)C=C1 Chemical compound C([C@@H](CO)NC(=O)N1CCC2=CN=C(N=C2C1)NC(C)C)C1=CC=C(Cl)C=C1 XLRDAQUUPXAIIS-KRWDZBQOSA-N 0.000 claims 1
- LJWQRITVDPDYOI-ROUUACIJSA-N C([C@@H]1O)C2=CC=CC=C2[C@@H]1NC(=O)N1CCC2=CN=C(NC(C)C)N=C2C1 Chemical compound C([C@@H]1O)C2=CC=CC=C2[C@@H]1NC(=O)N1CCC2=CN=C(NC(C)C)N=C2C1 LJWQRITVDPDYOI-ROUUACIJSA-N 0.000 claims 1
- WLTYLIXGUSMMEK-CQSZACIVSA-N C1([C@@H](C)NC(=O)N2CCC3=CN=C(N=C3C2)NC(C)C)=CC=CC=C1 Chemical compound C1([C@@H](C)NC(=O)N2CCC3=CN=C(N=C3C2)NC(C)C)=CC=CC=C1 WLTYLIXGUSMMEK-CQSZACIVSA-N 0.000 claims 1
- SHAIDSWCJFPTGT-GOSISDBHSA-N C1([C@@H](CO)NC(=O)N2CC=3C=C(N=CC=3CC2)NC(C)C)=CC=C(Cl)C(Cl)=C1 Chemical compound C1([C@@H](CO)NC(=O)N2CC=3C=C(N=CC=3CC2)NC(C)C)=CC=C(Cl)C(Cl)=C1 SHAIDSWCJFPTGT-GOSISDBHSA-N 0.000 claims 1
- KCOLUGZXTRUUFA-GOSISDBHSA-N C1([C@@H](CO)NC(=O)N2CC=3C=C(N=CC=3CC2)NC(C)C)=CC=C(F)C(Cl)=C1 Chemical compound C1([C@@H](CO)NC(=O)N2CC=3C=C(N=CC=3CC2)NC(C)C)=CC=C(F)C(Cl)=C1 KCOLUGZXTRUUFA-GOSISDBHSA-N 0.000 claims 1
- IWLUUFJXNMUTLO-UHFFFAOYSA-N C1=C(C#N)C(F)=CC(CNC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)=C1 Chemical compound C1=C(C#N)C(F)=CC(CNC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)=C1 IWLUUFJXNMUTLO-UHFFFAOYSA-N 0.000 claims 1
- UGERANQGDAVBDW-UHFFFAOYSA-N C1=C(C#N)C(F)=CC=C1CNC(=O)N1CC2=NC(NC3CCOCC3)=NC=C2CC1 Chemical compound C1=C(C#N)C(F)=CC=C1CNC(=O)N1CC2=NC(NC3CCOCC3)=NC=C2CC1 UGERANQGDAVBDW-UHFFFAOYSA-N 0.000 claims 1
- LSUMUNUFTHWMJZ-LBPRGKRZSA-N C1=C(Cl)C(OC)=CC(CNC(=O)N2CC3=NC(N[C@@H](C)CO)=NC=C3CC2)=C1 Chemical compound C1=C(Cl)C(OC)=CC(CNC(=O)N2CC3=NC(N[C@@H](C)CO)=NC=C3CC2)=C1 LSUMUNUFTHWMJZ-LBPRGKRZSA-N 0.000 claims 1
- PVQHOQLJXOKYAJ-LBPRGKRZSA-N C1=C(Cl)C(OC)=CC=C1CNC(=O)N1CC2=NC(N[C@@H](C)CO)=NC=C2CC1 Chemical compound C1=C(Cl)C(OC)=CC=C1CNC(=O)N1CC2=NC(N[C@@H](C)CO)=NC=C2CC1 PVQHOQLJXOKYAJ-LBPRGKRZSA-N 0.000 claims 1
- DCFJDVHPQHNHFB-UHFFFAOYSA-N C1=C(F)C(OC)=CC(CNC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)=C1 Chemical compound C1=C(F)C(OC)=CC(CNC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)=C1 DCFJDVHPQHNHFB-UHFFFAOYSA-N 0.000 claims 1
- QQGVTGNRCDDDIU-LBPRGKRZSA-N C1=C(F)C(OC)=CC=C1CNC(=O)N1CC2=NC(N[C@@H](C)CO)=NC=C2CC1 Chemical compound C1=C(F)C(OC)=CC=C1CNC(=O)N1CC2=NC(N[C@@H](C)CO)=NC=C2CC1 QQGVTGNRCDDDIU-LBPRGKRZSA-N 0.000 claims 1
- GLSYZEIUSBUAHC-ZDUSSCGKSA-N C1=C2NC=CC2=CC(CNC(=O)N2CCC3=CN=C(N=C3C2)N[C@H](CO)C)=C1 Chemical compound C1=C2NC=CC2=CC(CNC(=O)N2CCC3=CN=C(N=C3C2)N[C@H](CO)C)=C1 GLSYZEIUSBUAHC-ZDUSSCGKSA-N 0.000 claims 1
- UBCSEVWHDIVPGN-UHFFFAOYSA-N C1=CC(Cl)=CC=C1CNC(=O)N1CC2=NC(NC3CCOCC3)=NC=C2CC1 Chemical compound C1=CC(Cl)=CC=C1CNC(=O)N1CC2=NC(NC3CCOCC3)=NC=C2CC1 UBCSEVWHDIVPGN-UHFFFAOYSA-N 0.000 claims 1
- DJJXYTCNHUEJQN-UHFFFAOYSA-N C1=CC(F)=CC=C1CNC(=O)N1CC2=NC(NC3CCOCC3)=NC=C2CC1 Chemical compound C1=CC(F)=CC=C1CNC(=O)N1CC2=NC(NC3CCOCC3)=NC=C2CC1 DJJXYTCNHUEJQN-UHFFFAOYSA-N 0.000 claims 1
- QEMGXWBQOLZELW-UHFFFAOYSA-N C1=CC(OC(F)F)=CC=C1CNC(=O)N1CC2=NC(NC3CCOCC3)=NC=C2CC1 Chemical compound C1=CC(OC(F)F)=CC=C1CNC(=O)N1CC2=NC(NC3CCOCC3)=NC=C2CC1 QEMGXWBQOLZELW-UHFFFAOYSA-N 0.000 claims 1
- LZLPWQPOTACLHV-ZDUSSCGKSA-N C1=CC(SC)=CC=C1CNC(=O)N1CC2=NC(N[C@@H](C)CO)=NC=C2CC1 Chemical compound C1=CC(SC)=CC=C1CNC(=O)N1CC2=NC(N[C@@H](C)CO)=NC=C2CC1 LZLPWQPOTACLHV-ZDUSSCGKSA-N 0.000 claims 1
- MASKAVCFRKDXFC-UHFFFAOYSA-N C1=CC=C2NC(C(C)NC(=O)N3CCC4=CN=C(N=C4C3)NC(C)C)=NC2=C1 Chemical compound C1=CC=C2NC(C(C)NC(=O)N3CCC4=CN=C(N=C4C3)NC(C)C)=NC2=C1 MASKAVCFRKDXFC-UHFFFAOYSA-N 0.000 claims 1
- ZLKMJIZAFITLNS-LBPRGKRZSA-N C1=CC=C2SC(CNC(=O)N3CCC4=CN=C(N=C4C3)N[C@H](CO)C)=NC2=C1 Chemical compound C1=CC=C2SC(CNC(=O)N3CCC4=CN=C(N=C4C3)N[C@H](CO)C)=NC2=C1 ZLKMJIZAFITLNS-LBPRGKRZSA-N 0.000 claims 1
- SUQQXYPBPCSFCP-UHFFFAOYSA-N C1=NC(OC)=CC=C1CNC(=O)N1CC2=NC(NC3CCOCC3)=NC=C2CC1 Chemical compound C1=NC(OC)=CC=C1CNC(=O)N1CC2=NC(NC3CCOCC3)=NC=C2CC1 SUQQXYPBPCSFCP-UHFFFAOYSA-N 0.000 claims 1
- LQLMWLSPPDVSCO-UHFFFAOYSA-N C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NC(C)C1=NC=C(Cl)C=N1 Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NC(C)C1=NC=C(Cl)C=N1 LQLMWLSPPDVSCO-UHFFFAOYSA-N 0.000 claims 1
- BQQMPXLMVQGOAA-UHFFFAOYSA-N C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NC1(C=2C=C(F)C(Cl)=CC=2)CCNCC1 Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NC1(C=2C=C(F)C(Cl)=CC=2)CCNCC1 BQQMPXLMVQGOAA-UHFFFAOYSA-N 0.000 claims 1
- CLGUFUSVEHMAAL-UHFFFAOYSA-N C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NCC1=CC=C(C#N)C(F)=C1 Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NCC1=CC=C(C#N)C(F)=C1 CLGUFUSVEHMAAL-UHFFFAOYSA-N 0.000 claims 1
- LJUYBTAXQGTRCP-UHFFFAOYSA-N C1C2=NC(NC(CO)C)=NC=C2CCN1C(=O)NCC1=CC=C(Cl)C(OC(F)(F)F)=C1 Chemical compound C1C2=NC(NC(CO)C)=NC=C2CCN1C(=O)NCC1=CC=C(Cl)C(OC(F)(F)F)=C1 LJUYBTAXQGTRCP-UHFFFAOYSA-N 0.000 claims 1
- PKNRIGUBEBHGJB-LBPRGKRZSA-N C1C2=NC(N[C@H](CO)C)=NC=C2CCN1C(=O)NCC1=CC=C(C#N)C(F)=C1 Chemical compound C1C2=NC(N[C@H](CO)C)=NC=C2CCN1C(=O)NCC1=CC=C(C#N)C(F)=C1 PKNRIGUBEBHGJB-LBPRGKRZSA-N 0.000 claims 1
- XHMRWTBPFMOALB-ZDUSSCGKSA-N C1C2=NC(N[C@H](CO)C)=NC=C2CCN1C(=O)NCC1=CC=C(C#N)C=C1 Chemical compound C1C2=NC(N[C@H](CO)C)=NC=C2CCN1C(=O)NCC1=CC=C(C#N)C=C1 XHMRWTBPFMOALB-ZDUSSCGKSA-N 0.000 claims 1
- SREAXOZPYADIBW-ZDUSSCGKSA-N C1C2=NC(N[C@H](CO)C)=NC=C2CCN1C(=O)NCC1=CC=C(C)C(Cl)=C1 Chemical compound C1C2=NC(N[C@H](CO)C)=NC=C2CCN1C(=O)NCC1=CC=C(C)C(Cl)=C1 SREAXOZPYADIBW-ZDUSSCGKSA-N 0.000 claims 1
- ZMPBFQFJNMJJSU-ZDUSSCGKSA-N C1C2=NC(N[C@H](CO)C)=NC=C2CCN1C(=O)NCC1=CC=C(Cl)C(C)=C1 Chemical compound C1C2=NC(N[C@H](CO)C)=NC=C2CCN1C(=O)NCC1=CC=C(Cl)C(C)=C1 ZMPBFQFJNMJJSU-ZDUSSCGKSA-N 0.000 claims 1
- DOLHVEIAKODPTO-LBPRGKRZSA-N C1C2=NC(N[C@H](CO)C)=NC=C2CCN1C(=O)NCC1=CC=CC(C(F)(F)F)=C1 Chemical compound C1C2=NC(N[C@H](CO)C)=NC=C2CCN1C(=O)NCC1=CC=CC(C(F)(F)F)=C1 DOLHVEIAKODPTO-LBPRGKRZSA-N 0.000 claims 1
- FOUIUXQTYLWZAO-LBPRGKRZSA-N C1C2=NC(N[C@H](CO)C)=NC=C2CCN1C(=O)NCC1=CC=CC(Cl)=C1 Chemical compound C1C2=NC(N[C@H](CO)C)=NC=C2CCN1C(=O)NCC1=CC=CC(Cl)=C1 FOUIUXQTYLWZAO-LBPRGKRZSA-N 0.000 claims 1
- NYBKBYZDOVVKPV-UHFFFAOYSA-N C1CC2=CN=C(NC(C)C)N=C2CN1C(=O)NC(CC)C1=CC=C(C(F)(F)F)C(F)=C1 Chemical compound C1CC2=CN=C(NC(C)C)N=C2CN1C(=O)NC(CC)C1=CC=C(C(F)(F)F)C(F)=C1 NYBKBYZDOVVKPV-UHFFFAOYSA-N 0.000 claims 1
- NUBQOPHWNWFRPF-UHFFFAOYSA-N C1CC2=CN=C(NC3CCOCC3)N=C2CN1C(=O)NCC1=CC=CC=C1 Chemical compound C1CC2=CN=C(NC3CCOCC3)N=C2CN1C(=O)NCC1=CC=CC=C1 NUBQOPHWNWFRPF-UHFFFAOYSA-N 0.000 claims 1
- VFYNAYCSERVALN-UHFFFAOYSA-N C1CC2=CN=C(NC3CCOCC3)N=C2CN1C(=O)NCC1=CC=CC=N1 Chemical compound C1CC2=CN=C(NC3CCOCC3)N=C2CN1C(=O)NCC1=CC=CC=N1 VFYNAYCSERVALN-UHFFFAOYSA-N 0.000 claims 1
- WAVNVMYSJWQCLU-UHFFFAOYSA-N C1CC2=CN=C(NC3CCOCC3)N=C2CN1C(=O)NCC1=CC=CN=C1 Chemical compound C1CC2=CN=C(NC3CCOCC3)N=C2CN1C(=O)NCC1=CC=CN=C1 WAVNVMYSJWQCLU-UHFFFAOYSA-N 0.000 claims 1
- FUGYBDQKMIQTGG-UHFFFAOYSA-N C1CC2=CN=C(NC3CCOCC3)N=C2CN1C(=O)NCC1=CC=NC=C1 Chemical compound C1CC2=CN=C(NC3CCOCC3)N=C2CN1C(=O)NCC1=CC=NC=C1 FUGYBDQKMIQTGG-UHFFFAOYSA-N 0.000 claims 1
- CPPHCYKPFXQJBK-UHFFFAOYSA-N C1CC2=CN=C(NC3CCOCC3)N=C2CN1C(=O)NCC1=CN=CN=C1 Chemical compound C1CC2=CN=C(NC3CCOCC3)N=C2CN1C(=O)NCC1=CN=CN=C1 CPPHCYKPFXQJBK-UHFFFAOYSA-N 0.000 claims 1
- PXMPABHPKPQHJN-UHFFFAOYSA-N C1CC2=CN=C(NC3CCOCC3)N=C2CN1C(=O)NCC1=CN=CO1 Chemical compound C1CC2=CN=C(NC3CCOCC3)N=C2CN1C(=O)NCC1=CN=CO1 PXMPABHPKPQHJN-UHFFFAOYSA-N 0.000 claims 1
- ZVIRPVIYFWQIGP-UHFFFAOYSA-N C=1C=C2C=CNC2=CC=1CNC(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 Chemical compound C=1C=C2C=CNC2=CC=1CNC(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 ZVIRPVIYFWQIGP-UHFFFAOYSA-N 0.000 claims 1
- IOTIOAAKTFURDW-UHFFFAOYSA-N COC1=CC=CC(CNC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)=N1 Chemical compound COC1=CC=CC(CNC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)=N1 IOTIOAAKTFURDW-UHFFFAOYSA-N 0.000 claims 1
- JQVVIFXDUAXIDV-UHFFFAOYSA-N FC1=CN=CC(CNC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)=C1 Chemical compound FC1=CN=CC(CNC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)=C1 JQVVIFXDUAXIDV-UHFFFAOYSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- QWSYXQMUSXKUCN-HNNXBMFYSA-N N([C@@H](C)C=1C=CC=CC=1)C(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 QWSYXQMUSXKUCN-HNNXBMFYSA-N 0.000 claims 1
- OKHXEKRVPFFOFE-UHFFFAOYSA-N N-(1-methyl-4-phenylpyrrolidin-3-yl)-2-(oxan-4-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C=1C=CC=CC=1C1CN(C)CC1NC(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 OKHXEKRVPFFOFE-UHFFFAOYSA-N 0.000 claims 1
- PLBNHDHLNDZJCW-UHFFFAOYSA-N N-(2-phenylcyclopropyl)-2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NC1CC1C1=CC=CC=C1 PLBNHDHLNDZJCW-UHFFFAOYSA-N 0.000 claims 1
- GKZNHXMGIRXUSP-QGZVFWFLSA-N N-[(1R)-1-(3,4-dichlorophenyl)-3-hydroxypropyl]-2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1([C@@H](CCO)NC(=O)N2CCC3=CN=C(N=C3C2)NC(C)C)=CC=C(Cl)C(Cl)=C1 GKZNHXMGIRXUSP-QGZVFWFLSA-N 0.000 claims 1
- ULAFWTPMNQYCCY-LJQANCHMSA-N N-[(1R)-1-(3,4-dichlorophenyl)-3-hydroxypropyl]-7-(propan-2-ylamino)-3,4-dihydro-1H-2,6-naphthyridine-2-carboxamide Chemical compound C1([C@@H](CCO)NC(=O)N2CC=3C=C(N=CC=3CC2)NC(C)C)=CC=C(Cl)C(Cl)=C1 ULAFWTPMNQYCCY-LJQANCHMSA-N 0.000 claims 1
- XXOIZIIZZGQTTP-QGZVFWFLSA-N N-[(1R)-1-(4-fluorophenyl)-3-hydroxypropyl]-2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1([C@@H](CCO)NC(=O)N2CCC3=CN=C(N=C3C2)NC(C)C)=CC=C(F)C=C1 XXOIZIIZZGQTTP-QGZVFWFLSA-N 0.000 claims 1
- MYSDPHITQVVOIJ-OAHLLOKOSA-N N-[(1R)-1-cyclohexylethyl]-2-(oxan-4-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1(CCCCC1)[C@@H](C)NC(=O)N1CC=2N=C(N=CC2CC1)NC1CCOCC1 MYSDPHITQVVOIJ-OAHLLOKOSA-N 0.000 claims 1
- WYGXUAAIDRXAGU-QGZVFWFLSA-N N-[(1R)-3-amino-1-(3-chlorophenyl)propyl]-2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1([C@@H](CCN)NC(=O)N2CCC3=CN=C(N=C3C2)NC(C)C)=CC=CC(Cl)=C1 WYGXUAAIDRXAGU-QGZVFWFLSA-N 0.000 claims 1
- GOMVFWUINXVVRD-GOSISDBHSA-N N-[(1R)-3-cyano-1-(3,4-dichlorophenyl)propyl]-2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1([C@@H](CCC#N)NC(=O)N2CCC3=CN=C(N=C3C2)NC(C)C)=CC=C(Cl)C(Cl)=C1 GOMVFWUINXVVRD-GOSISDBHSA-N 0.000 claims 1
- GKZNHXMGIRXUSP-KRWDZBQOSA-N N-[(1S)-1-(3,4-dichlorophenyl)-3-hydroxypropyl]-2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1([C@H](CCO)NC(=O)N2CCC3=CN=C(N=C3C2)NC(C)C)=CC=C(Cl)C(Cl)=C1 GKZNHXMGIRXUSP-KRWDZBQOSA-N 0.000 claims 1
- VLYQISGSDMJXBZ-KRWDZBQOSA-N N-[(2S)-1-hydroxy-3-phenylpropan-2-yl]-2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C([C@@H](CO)NC(=O)N1CCC2=CN=C(N=C2C1)NC(C)C)C1=CC=CC=C1 VLYQISGSDMJXBZ-KRWDZBQOSA-N 0.000 claims 1
- GKZNHXMGIRXUSP-UHFFFAOYSA-N N-[1-(3,4-dichlorophenyl)-3-hydroxypropyl]-2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NC(CCO)C1=CC=C(Cl)C(Cl)=C1 GKZNHXMGIRXUSP-UHFFFAOYSA-N 0.000 claims 1
- DNGBBCRCJOPEHA-UHFFFAOYSA-N N-[1-(3,4-dichlorophenyl)ethyl]-7-[(3-hydroxycyclopentyl)amino]-3,4-dihydro-1H-2,6-naphthyridine-2-carboxamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C)NC(=O)N(CC1=C2)CCC1=CN=C2NC1CCC(O)C1 DNGBBCRCJOPEHA-UHFFFAOYSA-N 0.000 claims 1
- IXNFFSROLUSADZ-UHFFFAOYSA-N N-[1-(4-chloro-3-fluorophenyl)-3-hydroxypropyl]-2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NC(CCO)C1=CC=C(Cl)C(F)=C1 IXNFFSROLUSADZ-UHFFFAOYSA-N 0.000 claims 1
- AJHGUBGMDBYYMA-UHFFFAOYSA-N N-[4-(3,4-dichlorophenyl)pyrrolidin-3-yl]-2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NC1CNCC1C1=CC=C(Cl)C(Cl)=C1 AJHGUBGMDBYYMA-UHFFFAOYSA-N 0.000 claims 1
- DWRDGOIPPSOUNS-UHFFFAOYSA-N N-[4-(3,4-difluorophenyl)pyrrolidin-3-yl]-2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NC1CNCC1C1=CC=C(F)C(F)=C1 DWRDGOIPPSOUNS-UHFFFAOYSA-N 0.000 claims 1
- HIVASTWVSRAOGT-LBPRGKRZSA-N N-[[4-(difluoromethoxy)phenyl]methyl]-2-[[(2S)-1-hydroxypropan-2-yl]amino]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1C2=NC(N[C@H](CO)C)=NC=C2CCN1C(=O)NCC1=CC=C(OC(F)F)C=C1 HIVASTWVSRAOGT-LBPRGKRZSA-N 0.000 claims 1
- XTUVJUMINZSXGF-UHFFFAOYSA-N N-methylcyclohexylamine Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 claims 1
- YZFZSACYSVUQHH-UHFFFAOYSA-N N=1C2=CC=CC=C2NC=1C(C)NC(=O)N(CC1=N2)CCC1=CN=C2NC1=CC=C(F)C=C1 Chemical compound N=1C2=CC=CC=C2NC=1C(C)NC(=O)N(CC1=N2)CCC1=CN=C2NC1=CC=C(F)C=C1 YZFZSACYSVUQHH-UHFFFAOYSA-N 0.000 claims 1
- ZTVUQCHELWYPJU-WDEREUQCSA-N N[C@@H]([C@@H]1CCCN1)c1ccc(Cl)c(F)c1 Chemical compound N[C@@H]([C@@H]1CCCN1)c1ccc(Cl)c(F)c1 ZTVUQCHELWYPJU-WDEREUQCSA-N 0.000 claims 1
- WVMKIJVKOTZOOR-OAQYLSRUSA-N [(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]-[2-(oxan-4-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]methanone Chemical compound FC1=CC=C(F)C([C@@H]2N(CCC2)C(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)=C1 WVMKIJVKOTZOOR-OAQYLSRUSA-N 0.000 claims 1
- RICDEXKABJXDFF-UHFFFAOYSA-N [2-(oxan-4-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-(2-phenylazetidin-1-yl)methanone Chemical compound C1CC2=CN=C(NC3CCOCC3)N=C2CN1C(=O)N1CCC1C1=CC=CC=C1 RICDEXKABJXDFF-UHFFFAOYSA-N 0.000 claims 1
- BJVBZHGDGUONOU-UHFFFAOYSA-N [2-(oxan-4-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-(2-phenylpiperidin-1-yl)methanone Chemical compound C1CCCC(C=2C=CC=CC=2)N1C(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 BJVBZHGDGUONOU-UHFFFAOYSA-N 0.000 claims 1
- UXTAKWNNJUOQGL-UHFFFAOYSA-N [2-(oxan-4-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-(2-pyridin-3-ylpyrrolidin-1-yl)methanone Chemical compound C1CC2=CN=C(NC3CCOCC3)N=C2CN1C(=O)N1CCCC1C1=CC=CN=C1 UXTAKWNNJUOQGL-UHFFFAOYSA-N 0.000 claims 1
- GCSSFUPYLYPFDV-UHFFFAOYSA-N [2-(oxan-4-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-(3-phenylmorpholin-4-yl)methanone Chemical compound C1COCC(C=2C=CC=CC=2)N1C(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 GCSSFUPYLYPFDV-UHFFFAOYSA-N 0.000 claims 1
- ZMTPEIQAERZMKN-UHFFFAOYSA-N [2-(oxan-4-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-[2-(1,3-thiazol-2-yl)pyrrolidin-1-yl]methanone Chemical compound C1CC2=CN=C(NC3CCOCC3)N=C2CN1C(=O)N1CCCC1C1=NC=CS1 ZMTPEIQAERZMKN-UHFFFAOYSA-N 0.000 claims 1
- UBUYMKZIBKBLBF-UHFFFAOYSA-N [2-(oxan-4-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-(2-phenylpiperazin-1-yl)methanone Chemical compound C1CNCC(C=2C=CC=CC=2)N1C(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 UBUYMKZIBKBLBF-UHFFFAOYSA-N 0.000 claims 1
- SQBUZKFCCIEMGY-UHFFFAOYSA-N [2-(trifluoromethyl)pyrimidin-5-yl]methanamine Chemical compound NCC1=CN=C(C(F)(F)F)N=C1 SQBUZKFCCIEMGY-UHFFFAOYSA-N 0.000 claims 1
- ODSDBUOMHSEMBS-UHFFFAOYSA-N [2-chloro-4-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=C(C(F)(F)F)C=C1Cl ODSDBUOMHSEMBS-UHFFFAOYSA-N 0.000 claims 1
- OVFDZNSGNUXERC-UHFFFAOYSA-N [3-chloro-4-(trifluoromethoxy)phenyl]methanamine Chemical compound NCC1=CC=C(OC(F)(F)F)C(Cl)=C1 OVFDZNSGNUXERC-UHFFFAOYSA-N 0.000 claims 1
- GRCRXCBPWHSEOI-UHFFFAOYSA-N [3-chloro-4-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=C(C(F)(F)F)C(Cl)=C1 GRCRXCBPWHSEOI-UHFFFAOYSA-N 0.000 claims 1
- SRHQOQMNBVOXCF-UHFFFAOYSA-N [4-chloro-3-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=C(Cl)C(C(F)(F)F)=C1 SRHQOQMNBVOXCF-UHFFFAOYSA-N 0.000 claims 1
- QPMGRSWJTRAJIK-UHFFFAOYSA-N [4-methyl-3-(trifluoromethyl)phenyl]methanamine Chemical compound CC1=CC=C(CN)C=C1C(F)(F)F QPMGRSWJTRAJIK-UHFFFAOYSA-N 0.000 claims 1
- XPXVAYGVYBQKDE-UHFFFAOYSA-N [6-(trifluoromethyl)pyridin-3-yl]methanamine Chemical compound NCC1=CC=C(C(F)(F)F)N=C1 XPXVAYGVYBQKDE-UHFFFAOYSA-N 0.000 claims 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 1
- OCGBQTYNLPSKET-UHFFFAOYSA-N n-(1h-indol-2-ylmethyl)-2-(oxan-4-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C=1C2=CC=CC=C2NC=1CNC(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 OCGBQTYNLPSKET-UHFFFAOYSA-N 0.000 claims 1
- ALNNJHHLDMPFCI-QGZVFWFLSA-N n-[(1r)-1-(4-chlorophenyl)-3-hydroxypropyl]-2-(propan-2-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1([C@@H](CCO)NC(=O)N2CCC3=CN=C(N=C3C2)NC(C)C)=CC=C(Cl)C=C1 ALNNJHHLDMPFCI-QGZVFWFLSA-N 0.000 claims 1
- CDZIKVVMGVIWAM-QGZVFWFLSA-N n-[(1r)-3-amino-1-(4-chlorophenyl)propyl]-2-(propan-2-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1([C@@H](CCN)NC(=O)N2CCC3=CN=C(N=C3C2)NC(C)C)=CC=C(Cl)C=C1 CDZIKVVMGVIWAM-QGZVFWFLSA-N 0.000 claims 1
- WQZCQSZZPWAGRX-UHFFFAOYSA-N n-[1-(1h-indol-6-yl)ethyl]-2-(oxan-4-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C=1C=C2C=CNC2=CC=1C(C)NC(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 WQZCQSZZPWAGRX-UHFFFAOYSA-N 0.000 claims 1
- SOLSSSZVRNWMTM-UHFFFAOYSA-N n-[1-(3,4-difluorophenyl)-3-hydroxypropyl]-2-(propan-2-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NC(CCO)C1=CC=C(F)C(F)=C1 SOLSSSZVRNWMTM-UHFFFAOYSA-N 0.000 claims 1
- JLFWORHZSACMOG-UHFFFAOYSA-N n-[3-(aminomethyl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(CN)=C1 JLFWORHZSACMOG-UHFFFAOYSA-N 0.000 claims 1
- HPYMUBZLXVMIJI-UHFFFAOYSA-N n-[3-amino-1-(3,4-dichlorophenyl)propyl]-2-(propan-2-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NC(CCN)C1=CC=C(Cl)C(Cl)=C1 HPYMUBZLXVMIJI-UHFFFAOYSA-N 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract description 6
- 125000004995 haloalkylthio group Chemical group 0.000 abstract description 5
- AXLOCHLTNQDFFS-BESJYZOMSA-N azastene Chemical compound C([C@H]1[C@@H]2CC[C@@]([C@]2(CC[C@@H]1[C@@]1(C)C2)C)(O)C)C=C1C(C)(C)C1=C2C=NO1 AXLOCHLTNQDFFS-BESJYZOMSA-N 0.000 abstract description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 268
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 165
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 138
- 239000000243 solution Substances 0.000 description 136
- 238000006243 chemical reaction Methods 0.000 description 114
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 111
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 109
- 238000000034 method Methods 0.000 description 85
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 83
- 235000019439 ethyl acetate Nutrition 0.000 description 68
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 61
- 238000004587 chromatography analysis Methods 0.000 description 53
- 229910052681 coesite Inorganic materials 0.000 description 53
- 229910052682 stishovite Inorganic materials 0.000 description 53
- 229910052905 tridymite Inorganic materials 0.000 description 53
- 229910052906 cristobalite Inorganic materials 0.000 description 52
- 239000000377 silicon dioxide Substances 0.000 description 52
- 235000012239 silicon dioxide Nutrition 0.000 description 52
- 239000012043 crude product Substances 0.000 description 46
- 239000012074 organic phase Substances 0.000 description 42
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
- 239000007787 solid Substances 0.000 description 40
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 38
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 37
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- 238000005160 1H NMR spectroscopy Methods 0.000 description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 26
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 238000000746 purification Methods 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 238000009833 condensation Methods 0.000 description 17
- 230000005494 condensation Effects 0.000 description 17
- 239000012071 phase Substances 0.000 description 17
- 239000003921 oil Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 238000005481 NMR spectroscopy Methods 0.000 description 14
- 125000002947 alkylene group Chemical group 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 12
- 238000000926 separation method Methods 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 150000003254 radicals Chemical class 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000012299 nitrogen atmosphere Substances 0.000 description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- 150000001721 carbon Chemical group 0.000 description 8
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000004808 supercritical fluid chromatography Methods 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 7
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 6
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 125000004414 alkyl thio group Chemical group 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 229960004592 isopropanol Drugs 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- RMXGWLUCCKWPGK-UHFFFAOYSA-M magnesium;1,2-dichlorobenzene-5-ide;bromide Chemical compound [Mg+2].[Br-].ClC1=CC=[C-]C=C1Cl RMXGWLUCCKWPGK-UHFFFAOYSA-M 0.000 description 6
- GBIXREWYSCYTGZ-UHFFFAOYSA-M magnesium;1-chloro-2-fluorobenzene-4-ide;bromide Chemical group [Mg+2].[Br-].FC1=C[C-]=CC=C1Cl GBIXREWYSCYTGZ-UHFFFAOYSA-M 0.000 description 6
- OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 6
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical group C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 5
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 5
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 5
- 125000003282 alkyl amino group Chemical group 0.000 description 5
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 5
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 229910052702 rhenium Inorganic materials 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- OEPBVXQEVBURGC-UHFFFAOYSA-N 4-bromo-2-fluoro-1-(trifluoromethyl)benzene Chemical compound FC1=CC(Br)=CC=C1C(F)(F)F OEPBVXQEVBURGC-UHFFFAOYSA-N 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- MZRAWKRBTTVLPE-UHFFFAOYSA-N Cl.Cl.NC1=NC=CC=N1 Chemical compound Cl.Cl.NC1=NC=CC=N1 MZRAWKRBTTVLPE-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000008228 bacteriostatic water for injection Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 235000013877 carbamide Nutrition 0.000 description 4
- 238000004296 chiral HPLC Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 229960002949 fluorouracil Drugs 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 4
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 4
- 150000003230 pyrimidines Chemical class 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 150000003335 secondary amines Chemical class 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 238000000844 transformation Methods 0.000 description 4
- UWAVHFUELKOLTB-SBSPUUFOSA-N (1r)-1-(4-chloro-3-fluorophenyl)propan-1-amine;hydrochloride Chemical compound Cl.CC[C@@H](N)C1=CC=C(Cl)C(F)=C1 UWAVHFUELKOLTB-SBSPUUFOSA-N 0.000 description 3
- XOSGUVTXBPPKIP-CYBMUJFWSA-N (1s)-2-[tert-butyl(dimethyl)silyl]oxy-1-(4-chloro-3-fluorophenyl)ethanamine Chemical compound CC(C)(C)[Si](C)(C)OC[C@@H](N)C1=CC=C(Cl)C(F)=C1 XOSGUVTXBPPKIP-CYBMUJFWSA-N 0.000 description 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 3
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 3
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- HUNAWQNQRQSVEE-WHFBIAKZSA-N 2-[(1s,3s)-3-hydroxycyclopentyl]guanidine Chemical compound NC(=N)N[C@H]1CC[C@H](O)C1 HUNAWQNQRQSVEE-WHFBIAKZSA-N 0.000 description 3
- PUKXPXHAEQJRKP-UHFFFAOYSA-N 2-[tert-butyl(dimethyl)silyl]oxy-1-(4-chloro-3-fluorophenyl)ethanone Chemical compound CC(C)(C)[Si](C)(C)OCC(=O)C1=CC=C(Cl)C(F)=C1 PUKXPXHAEQJRKP-UHFFFAOYSA-N 0.000 description 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
- 235000019502 Orange oil Nutrition 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 3
- 125000004103 aminoalkyl group Chemical group 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 3
- 150000005840 aryl radicals Chemical class 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 150000001540 azides Chemical class 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- KHYAFFAGZNCWPT-UHFFFAOYSA-N boron;n,n-diethylaniline Chemical compound [B].CCN(CC)C1=CC=CC=C1 KHYAFFAGZNCWPT-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 3
- 125000004663 dialkyl amino group Chemical group 0.000 description 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 3
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000003821 enantio-separation Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000001640 fractional crystallisation Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 239000012948 isocyanate Substances 0.000 description 3
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- LLYZIEJMGVNMNJ-LBPRGKRZSA-N n-[(2s)-1-[tert-butyl(dimethyl)silyl]oxypropan-2-yl]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-amine Chemical compound C1CNCC2=NC(N[C@H](CO[Si](C)(C)C(C)(C)C)C)=NC=C21 LLYZIEJMGVNMNJ-LBPRGKRZSA-N 0.000 description 3
- ZTXAUJJTZSOBRX-NRFANRHFSA-N n-[(s)-(3,4-dichlorophenyl)-(1,3-oxazol-5-yl)methyl]-2-(oxan-4-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1[C@@H](C=1OC=NC=1)NC(=O)N1CC2=NC(NC3CCOCC3)=NC=C2CC1 ZTXAUJJTZSOBRX-NRFANRHFSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000010502 orange oil Substances 0.000 description 3
- 238000006053 organic reaction Methods 0.000 description 3
- PUPAWTXNPAJCHR-UHFFFAOYSA-N oxazaborole Chemical compound O1C=CB=N1 PUPAWTXNPAJCHR-UHFFFAOYSA-N 0.000 description 3
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 3
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000012746 preparative thin layer chromatography Methods 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 3
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- OYVVKCJFSGWRSI-NTMALXAHSA-N tert-butyl (4z)-4-(dimethylaminomethylidene)-3-oxopiperidine-1-carboxylate Chemical compound CN(C)\C=C1\CCN(C(=O)OC(C)(C)C)CC1=O OYVVKCJFSGWRSI-NTMALXAHSA-N 0.000 description 3
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 3
- 229910052727 yttrium Inorganic materials 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- WDNFBDITRUKREU-SNVBAGLBSA-N (1R)-1-(3,4-dichlorophenyl)-3-methoxypropan-1-amine Chemical compound COCC[C@@H](N)C1=CC=C(Cl)C(Cl)=C1 WDNFBDITRUKREU-SNVBAGLBSA-N 0.000 description 2
- ZUJSEHSBTFCPLE-ZDUSSCGKSA-N (1R)-2-[tert-butyl(dimethyl)silyl]oxy-1-(3,4-dichlorophenyl)ethanol Chemical compound CC(C)(C)[Si](C)(C)OC[C@H](O)C1=CC=C(Cl)C(Cl)=C1 ZUJSEHSBTFCPLE-ZDUSSCGKSA-N 0.000 description 2
- JGOIWTAAYYAMKP-RXMQYKEDSA-N (1r)-1-[3-fluoro-4-(trifluoromethyl)phenyl]ethanamine Chemical compound C[C@@H](N)C1=CC=C(C(F)(F)F)C(F)=C1 JGOIWTAAYYAMKP-RXMQYKEDSA-N 0.000 description 2
- LPQFPLJRYJOIMC-SECBINFHSA-N (1r)-1-[3-fluoro-4-(trifluoromethyl)phenyl]propan-1-amine Chemical compound CC[C@@H](N)C1=CC=C(C(F)(F)F)C(F)=C1 LPQFPLJRYJOIMC-SECBINFHSA-N 0.000 description 2
- MZTXVLFYEKCSAQ-HZMBPMFUSA-N (1r,2s)-2-[tert-butyl(dimethyl)silyl]oxy-1-[2-fluoro-3-(trifluoromethyl)phenyl]propan-1-ol Chemical compound CC(C)(C)[Si](C)(C)O[C@@H](C)[C@H](O)C1=CC=CC(C(F)(F)F)=C1F MZTXVLFYEKCSAQ-HZMBPMFUSA-N 0.000 description 2
- YHFYRVZIONNYSM-WHFBIAKZSA-N (1s,3s)-3-aminocyclopentan-1-ol Chemical compound N[C@H]1CC[C@H](O)C1 YHFYRVZIONNYSM-WHFBIAKZSA-N 0.000 description 2
- SOHVXIKSDRCCCY-JTQLQIEISA-N (2s)-2-[tert-butyl(dimethyl)silyl]oxy-1-[2-fluoro-3-(trifluoromethyl)phenyl]propan-1-one Chemical compound CC(C)(C)[Si](C)(C)O[C@@H](C)C(=O)C1=CC=CC(C(F)(F)F)=C1F SOHVXIKSDRCCCY-JTQLQIEISA-N 0.000 description 2
- DHZBEQJOROMVKH-UHFFFAOYSA-N (3,4-dichlorophenyl)-(1,3-oxazol-5-yl)methanamine;hydrochloride Chemical compound Cl.C=1C=C(Cl)C(Cl)=CC=1C(N)C1=CN=CO1 DHZBEQJOROMVKH-UHFFFAOYSA-N 0.000 description 2
- JLBNTSOODSYBQO-SNVBAGLBSA-N (3s)-3-(4-chloro-3-fluorophenyl)-4-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)(C)OC(=O)NC[C@@H](CC(O)=O)C1=CC=C(Cl)C(F)=C1 JLBNTSOODSYBQO-SNVBAGLBSA-N 0.000 description 2
- VTFYYBIAJQLYJM-UHFFFAOYSA-N (4-chloro-3-fluorophenyl)-(1h-pyrazol-4-yl)methanamine Chemical compound C=1C=C(Cl)C(F)=CC=1C(N)C=1C=NNC=1 VTFYYBIAJQLYJM-UHFFFAOYSA-N 0.000 description 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 2
- GSIPOZWLYGLXDM-UHFFFAOYSA-N 1,2-oxazole-5-carbaldehyde Chemical compound O=CC1=CC=NO1 GSIPOZWLYGLXDM-UHFFFAOYSA-N 0.000 description 2
- YOFJBRZKRZUDGB-UHFFFAOYSA-N 1,3-oxazole-5-carbaldehyde Chemical compound O=CC1=CN=CO1 YOFJBRZKRZUDGB-UHFFFAOYSA-N 0.000 description 2
- YWBUNUGOMAFWHQ-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-2,2,2-trifluoroethanone Chemical compound FC(F)(F)C(=O)C1=CC=C(Cl)C(Cl)=C1 YWBUNUGOMAFWHQ-UHFFFAOYSA-N 0.000 description 2
- GBHNWWAAJIPAFF-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-2-methylpropan-1-amine Chemical compound CC(C)C(N)C1=CC=C(Cl)C(Cl)=C1 GBHNWWAAJIPAFF-UHFFFAOYSA-N 0.000 description 2
- BVKHCVHYQNGCSC-UHFFFAOYSA-N 1-(3-chloro-5-fluorophenyl)ethanone Chemical compound CC(=O)C1=CC(F)=CC(Cl)=C1 BVKHCVHYQNGCSC-UHFFFAOYSA-N 0.000 description 2
- ATZHNDSADJDUPJ-UHFFFAOYSA-N 1-(4-chloro-3-fluorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)C(F)=C1 ATZHNDSADJDUPJ-UHFFFAOYSA-N 0.000 description 2
- NXQBONPKAOTSNA-UHFFFAOYSA-N 1-[3-fluoro-4-(trifluoromethyl)phenyl]ethanone Chemical compound CC(=O)C1=CC=C(C(F)(F)F)C(F)=C1 NXQBONPKAOTSNA-UHFFFAOYSA-N 0.000 description 2
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 description 2
- MYFZXSOYJVWTBL-UHFFFAOYSA-N 1-methylpyrazole-4-carbaldehyde Chemical compound CN1C=C(C=O)C=N1 MYFZXSOYJVWTBL-UHFFFAOYSA-N 0.000 description 2
- RBZRMBCLZMEYEH-UHFFFAOYSA-N 1h-pyrazol-1-ium-1-carboximidamide;chloride Chemical compound Cl.NC(=N)N1C=CC=N1 RBZRMBCLZMEYEH-UHFFFAOYSA-N 0.000 description 2
- LJKATJHBJPFKBQ-UHFFFAOYSA-N 2-(oxan-2-yl)pyrazole-3-carbaldehyde Chemical compound O=CC1=CC=NN1C1OCCCC1 LJKATJHBJPFKBQ-UHFFFAOYSA-N 0.000 description 2
- UJHRDKSPSDMKCL-VKHMYHEASA-N 2-[(2s)-1-hydroxypropan-2-yl]guanidine Chemical compound OC[C@H](C)NC(N)=N UJHRDKSPSDMKCL-VKHMYHEASA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 2
- JESRNIJXVIFVOV-UHFFFAOYSA-N 2-methylpyrazol-3-amine Chemical compound CN1N=CC=C1N JESRNIJXVIFVOV-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 description 2
- VTXNOVCTHUBABW-UHFFFAOYSA-N 3,4-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C(Cl)=C1 VTXNOVCTHUBABW-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 2
- AZMDWRPTDCIFRD-UHFFFAOYSA-N 4-chloro-3-fluorobenzaldehyde Chemical compound FC1=CC(C=O)=CC=C1Cl AZMDWRPTDCIFRD-UHFFFAOYSA-N 0.000 description 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical class CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- GGRIMCBKABRONH-WDEREUQCSA-N C1([C@@H](C)NC(=O)N2CCC3=CN=C(N=C3C2)N[C@H](CO)C)=CC(F)=C(Cl)C=C1F Chemical compound C1([C@@H](C)NC(=O)N2CCC3=CN=C(N=C3C2)N[C@H](CO)C)=CC(F)=C(Cl)C=C1F GGRIMCBKABRONH-WDEREUQCSA-N 0.000 description 2
- USJVEDZNWMSYCX-NWDGAFQWSA-N C1([C@@H](C)NC(=O)N2CCC3=CN=C(N=C3C2)N[C@H](CO)C)=CC=C(F)C(Cl)=C1 Chemical compound C1([C@@H](C)NC(=O)N2CCC3=CN=C(N=C3C2)N[C@H](CO)C)=CC=C(F)C(Cl)=C1 USJVEDZNWMSYCX-NWDGAFQWSA-N 0.000 description 2
- AXEPOYHEIGAEII-ORAYPTAESA-N C1([C@H](NC(=O)N2CC3=NC(N[C@@H](C)CO)=NC=C3CC2)C(C)C)=CC=C(Cl)C(Cl)=C1 Chemical compound C1([C@H](NC(=O)N2CC3=NC(N[C@@H](C)CO)=NC=C3CC2)C(C)C)=CC=C(Cl)C(Cl)=C1 AXEPOYHEIGAEII-ORAYPTAESA-N 0.000 description 2
- ACGYRUUQLSTTHZ-YVEFUNNKSA-N C1([C@H](NC(=O)N2CC3=NC(N[C@@H](C)CO)=NC=C3CC2)CC)=CC=C(Cl)C(F)=C1 Chemical compound C1([C@H](NC(=O)N2CC3=NC(N[C@@H](C)CO)=NC=C3CC2)CC)=CC=C(Cl)C(F)=C1 ACGYRUUQLSTTHZ-YVEFUNNKSA-N 0.000 description 2
- XDQYSWXJHXGIQY-NRFANRHFSA-N C1=C(Cl)C(F)=CC([C@H](NC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)C2=CNN=C2)=C1 Chemical compound C1=C(Cl)C(F)=CC([C@H](NC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)C2=CNN=C2)=C1 XDQYSWXJHXGIQY-NRFANRHFSA-N 0.000 description 2
- HULGRXXRPMJZDB-CYBMUJFWSA-N C1=NN(CC)C=C1NC1=NC=C(CCN(C2)C(=O)N[C@H](C)C=3C=C(Cl)C(Cl)=CC=3)C2=N1 Chemical compound C1=NN(CC)C=C1NC1=NC=C(CCN(C2)C(=O)N[C@H](C)C=3C=C(Cl)C(Cl)=CC=3)C2=N1 HULGRXXRPMJZDB-CYBMUJFWSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical class [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 239000012824 ERK inhibitor Substances 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- YAPHYTGMHOVSIV-CQSZACIVSA-N N([C@H](C)C=1C=C(Cl)C(Cl)=CC=1)C(=O)N(CC1=N2)CCC1=CN=C2NC1CCN(C)CC1 Chemical compound N([C@H](C)C=1C=C(Cl)C(Cl)=CC=1)C(=O)N(CC1=N2)CCC1=CN=C2NC1CCN(C)CC1 YAPHYTGMHOVSIV-CQSZACIVSA-N 0.000 description 2
- GPFDNZZGHDDRLN-KCXAZCMYSA-N N([C@H](C)C=1C=C(F)C(=CC=1)C(F)(F)F)C(=O)N(CC1=N2)CCC1=CN=C2N[C@H]1CC[C@H](O)C1 Chemical compound N([C@H](C)C=1C=C(F)C(=CC=1)C(F)(F)F)C(=O)N(CC1=N2)CCC1=CN=C2N[C@H]1CC[C@H](O)C1 GPFDNZZGHDDRLN-KCXAZCMYSA-N 0.000 description 2
- CPRIWTOHFJPMKX-CQSZACIVSA-N N([C@H](C)C=1C=CC(F)=CC=1)C(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 Chemical compound N([C@H](C)C=1C=CC(F)=CC=1)C(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 CPRIWTOHFJPMKX-CQSZACIVSA-N 0.000 description 2
- UDHMEFPBIKNDFJ-TXPKVOOTSA-N N([C@H](CC)C=1C=C(F)C(=CC=1)C(F)(F)F)C(=O)N(CC1=N2)CCC1=CN=C2N[C@H]1CC[C@H](O)C1 Chemical compound N([C@H](CC)C=1C=C(F)C(=CC=1)C(F)(F)F)C(=O)N(CC1=N2)CCC1=CN=C2N[C@H]1CC[C@H](O)C1 UDHMEFPBIKNDFJ-TXPKVOOTSA-N 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- ONJPSNVYQQQVOK-CYBMUJFWSA-N N-[(1R)-1-(3,4-dichlorophenyl)ethyl]-2-(oxan-4-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound N([C@H](C)C=1C=C(Cl)C(Cl)=CC=1)C(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 ONJPSNVYQQQVOK-CYBMUJFWSA-N 0.000 description 2
- DKWKSRUXEXEYIL-CQSZACIVSA-N N-[(1R)-1-(4-chlorophenyl)ethyl]-2-(oxan-4-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound N([C@H](C)C=1C=CC(Cl)=CC=1)C(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 DKWKSRUXEXEYIL-CQSZACIVSA-N 0.000 description 2
- INPIKHRXRRIOJM-VXKWHMMOSA-N N-[(S)-[(2S)-1-acetylpyrrolidin-2-yl]-(4-chloro-3-fluorophenyl)methyl]-2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C([C@H]1[C@@H](NC(=O)N2CCC3=CN=C(N=C3C2)NC(C)C)C=2C=C(F)C(Cl)=CC=2)CCN1C(C)=O INPIKHRXRRIOJM-VXKWHMMOSA-N 0.000 description 2
- VXDYYJPLOFIVKA-QUCCMNQESA-N N-[(S)-[3-fluoro-4-(trifluoromethyl)phenyl]-[(2R)-pyrrolidin-2-yl]methyl]-2-(propan-2-ylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C([C@@H]1[C@@H](NC(=O)N2CCC3=CN=C(N=C3C2)NC(C)C)C=2C=C(F)C(=CC=2)C(F)(F)F)CCN1 VXDYYJPLOFIVKA-QUCCMNQESA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical class C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001414 amino alcohols Chemical class 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- 229960003437 aminoglutethimide Drugs 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 125000005141 aryl amino sulfonyl group Chemical group 0.000 description 2
- 125000005116 aryl carbamoyl group Chemical group 0.000 description 2
- 125000005129 aryl carbonyl group Chemical group 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 125000005110 aryl thio group Chemical group 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 2
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002085 enols Chemical group 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229940087476 femara Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 229960004338 leuprorelin Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- HXRAMSFGUAOAJR-UHFFFAOYSA-N n,n,n',n'-tetramethyl-1-[(2-methylpropan-2-yl)oxy]methanediamine Chemical compound CN(C)C(N(C)C)OC(C)(C)C HXRAMSFGUAOAJR-UHFFFAOYSA-N 0.000 description 2
- YILLOVXFYLQYOD-UHFFFAOYSA-N n-(4-chloro-3-fluorophenyl)-n,1-dimethylpyrazol-3-amine Chemical compound C=1C=C(Cl)C(F)=CC=1N(C)C=1C=CN(C)N=1 YILLOVXFYLQYOD-UHFFFAOYSA-N 0.000 description 2
- FRTYRCPWNXQGNU-UHFFFAOYSA-N n-(4-chloro-3-fluorophenyl)-n,1-dimethylpyrazol-4-amine Chemical compound C=1C=C(Cl)C(F)=CC=1N(C)C=1C=NN(C)C=1 FRTYRCPWNXQGNU-UHFFFAOYSA-N 0.000 description 2
- OKHSITBCKZXSAM-HXUWFJFHSA-N n-[(1r)-1-(3,4-dichlorophenyl)-3-methoxypropyl]-2-(oxan-4-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound N([C@H](CCOC)C=1C=C(Cl)C(Cl)=CC=1)C(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 OKHSITBCKZXSAM-HXUWFJFHSA-N 0.000 description 2
- UFPJNNFZCVYLKA-GFCCVEGCSA-N n-[(1r)-1-(3,4-dichlorophenyl)ethyl]-2-[(2-methylpyrazol-3-yl)amino]-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound N([C@H](C)C=1C=C(Cl)C(Cl)=CC=1)C(=O)N(CC1=N2)CCC1=CN=C2NC1=CC=NN1C UFPJNNFZCVYLKA-GFCCVEGCSA-N 0.000 description 2
- HRCGSBHCRJQDMC-NWDGAFQWSA-N n-[(1r)-1-(3,4-dichlorophenyl)ethyl]-2-[[(2s)-1-hydroxypropan-2-yl]amino]-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1([C@@H](C)NC(=O)N2CCC3=CN=C(N=C3C2)N[C@H](CO)C)=CC=C(Cl)C(Cl)=C1 HRCGSBHCRJQDMC-NWDGAFQWSA-N 0.000 description 2
- GXFPLMWXKGNTSJ-TXPKVOOTSA-N n-[(1r)-1-(3,4-dichlorophenyl)propyl]-2-[[(1s,3s)-3-hydroxycyclopentyl]amino]-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound N([C@H](CC)C=1C=C(Cl)C(Cl)=CC=1)C(=O)N(CC1=N2)CCC1=CN=C2N[C@H]1CC[C@H](O)C1 GXFPLMWXKGNTSJ-TXPKVOOTSA-N 0.000 description 2
- XHQBOSUFOHFXGZ-CYBMUJFWSA-N n-[(1r)-1-(4-chloro-3-fluorophenyl)ethyl]-2-(oxan-4-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound N([C@H](C)C=1C=C(F)C(Cl)=CC=1)C(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 XHQBOSUFOHFXGZ-CYBMUJFWSA-N 0.000 description 2
- KSAARAGFPBZEGM-NWDGAFQWSA-N n-[(1r)-1-(4-chloro-3-fluorophenyl)ethyl]-2-[[(2s)-1-hydroxypropan-2-yl]amino]-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1([C@@H](C)NC(=O)N2CCC3=CN=C(N=C3C2)N[C@H](CO)C)=CC=C(Cl)C(F)=C1 KSAARAGFPBZEGM-NWDGAFQWSA-N 0.000 description 2
- JDXNNECSPJJCPZ-QFYYESIMSA-N n-[(1s)-1-(3,4-dichlorophenyl)-2,2,2-trifluoroethyl]-2-[[(2s)-1-hydroxypropan-2-yl]amino]-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1([C@H](NC(=O)N2CCC3=CN=C(N=C3C2)N[C@H](CO)C)C(F)(F)F)=CC=C(Cl)C(Cl)=C1 JDXNNECSPJJCPZ-QFYYESIMSA-N 0.000 description 2
- KPLDUFFSXVTMOF-LJQANCHMSA-N n-[(1s)-1-(3,4-dichlorophenyl)-2-hydroxyethyl]-2-(oxan-4-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound N([C@H](CO)C=1C=C(Cl)C(Cl)=CC=1)C(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 KPLDUFFSXVTMOF-LJQANCHMSA-N 0.000 description 2
- OJRJASQFNLOAKZ-LJQANCHMSA-N n-[(1s)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-2-(oxan-4-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound N([C@H](CO)C=1C=C(F)C(Cl)=CC=1)C(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 OJRJASQFNLOAKZ-LJQANCHMSA-N 0.000 description 2
- KTGAVTSPCORIBP-KZULUSFZSA-N n-[(1s,2r)-1-[2-fluoro-3-(trifluoromethyl)phenyl]-2-hydroxypropyl]-2-(propan-2-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1([C@@H]([C@@H](C)O)NC(=O)N2CCC3=CN=C(N=C3C2)NC(C)C)=CC=CC(C(F)(F)F)=C1F KTGAVTSPCORIBP-KZULUSFZSA-N 0.000 description 2
- KTGAVTSPCORIBP-KPZWWZAWSA-N n-[(1s,2s)-1-[2-fluoro-3-(trifluoromethyl)phenyl]-2-hydroxypropyl]-2-(propan-2-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1([C@@H]([C@H](C)O)NC(=O)N2CCC3=CN=C(N=C3C2)NC(C)C)=CC=CC(C(F)(F)F)=C1F KTGAVTSPCORIBP-KPZWWZAWSA-N 0.000 description 2
- ZTXAUJJTZSOBRX-UHFFFAOYSA-N n-[(3,4-dichlorophenyl)-(1,3-oxazol-5-yl)methyl]-2-(oxan-4-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C=1OC=NC=1)NC(=O)N1CC2=NC(NC3CCOCC3)=NC=C2CC1 ZTXAUJJTZSOBRX-UHFFFAOYSA-N 0.000 description 2
- PTBJCVIPQRJTKB-UHFFFAOYSA-N n-[(4-chloro-3-fluorophenyl)-(1,3-oxazol-5-yl)methyl]-2-(oxan-4-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1=C(Cl)C(F)=CC(C(NC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)C=2OC=NC=2)=C1 PTBJCVIPQRJTKB-UHFFFAOYSA-N 0.000 description 2
- XDQYSWXJHXGIQY-UHFFFAOYSA-N n-[(4-chloro-3-fluorophenyl)-(1h-pyrazol-4-yl)methyl]-2-(oxan-4-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1=C(Cl)C(F)=CC(C(NC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)C2=CNN=C2)=C1 XDQYSWXJHXGIQY-UHFFFAOYSA-N 0.000 description 2
- FPJGZVMSDCCSEC-NRFANRHFSA-N n-[(s)-(3,4-dichlorophenyl)-(1h-pyrazol-5-yl)methyl]-2-(oxan-4-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1[C@@H](C=1NN=CC=1)NC(=O)N1CC2=NC(NC3CCOCC3)=NC=C2CC1 FPJGZVMSDCCSEC-NRFANRHFSA-N 0.000 description 2
- IZXDFTLUYDUMQF-NRFANRHFSA-N n-[(s)-(4-chloro-3-fluorophenyl)-(1,2-oxazol-5-yl)methyl]-2-(oxan-4-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1=C(Cl)C(F)=CC([C@H](NC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)C=2ON=CC=2)=C1 IZXDFTLUYDUMQF-NRFANRHFSA-N 0.000 description 2
- RJQKYKXLMAEYIP-CHPOKUKFSA-N n-[1-(3,4-dichlorophenyl)-3,3,3-trifluoropropyl]-2-[[(2s)-1-hydroxypropan-2-yl]amino]-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1C2=NC(N[C@H](CO)C)=NC=C2CCN1C(=O)NC(CC(F)(F)F)C1=CC=C(Cl)C(Cl)=C1 RJQKYKXLMAEYIP-CHPOKUKFSA-N 0.000 description 2
- MGTSLJNTEQODFJ-UHFFFAOYSA-N n-[[3-fluoro-4-(trifluoromethoxy)phenyl]-(1,3-oxazol-5-yl)methyl]-2-methylpropane-2-sulfinamide Chemical compound C=1C=C(OC(F)(F)F)C(F)=CC=1C(NS(=O)C(C)(C)C)C1=CN=CO1 MGTSLJNTEQODFJ-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 125000003884 phenylalkyl group Chemical group 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- LFILDSDQMSCNBV-LURJTMIESA-N propane-2-sulfinamide Chemical compound CC(C)[S@@](N)=O LFILDSDQMSCNBV-LURJTMIESA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- YDVHAJGGRNBAER-UHFFFAOYSA-N pyrimidin-2-amine;hydrochloride Chemical compound Cl.NC1=NC=CC=N1 YDVHAJGGRNBAER-UHFFFAOYSA-N 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- SRKXVESHUPPYMO-UHFFFAOYSA-N quinazoline-7-carboxylic acid Chemical compound C1=NC=NC2=CC(C(=O)O)=CC=C21 SRKXVESHUPPYMO-UHFFFAOYSA-N 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000007142 ring opening reaction Methods 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 2
- GYUMEBOHTRVDLK-KWCCSABGSA-N tert-butyl (2R)-2-[[4-chloro-3-(trifluoromethyl)phenyl]-hydroxymethyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1C(O)c1ccc(Cl)c(c1)C(F)(F)F GYUMEBOHTRVDLK-KWCCSABGSA-N 0.000 description 2
- LPQZERIRKRYGGM-UHFFFAOYSA-N tert-butyl pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1 LPQZERIRKRYGGM-UHFFFAOYSA-N 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000017105 transposition Effects 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- ABYUHMWSIOTQKT-SBSPUUFOSA-N (1R)-1-[4-(trifluoromethyl)phenyl]propan-1-amine hydrochloride Chemical compound Cl.CC[C@@H](N)C1=CC=C(C(F)(F)F)C=C1 ABYUHMWSIOTQKT-SBSPUUFOSA-N 0.000 description 1
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- PINPOEWMCLFRRB-ZCFIWIBFSA-N (1r)-1-(4-chlorophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=C(Cl)C=C1 PINPOEWMCLFRRB-ZCFIWIBFSA-N 0.000 description 1
- JVLWNYKROJNLAS-FYZOBXCZSA-N (1r)-1-[4-(trifluoromethyl)phenyl]ethanamine;hydrochloride Chemical compound Cl.C[C@@H](N)C1=CC=C(C(F)(F)F)C=C1 JVLWNYKROJNLAS-FYZOBXCZSA-N 0.000 description 1
- AQFLVLHRZFLDDV-SECBINFHSA-N (1r)-1-phenylpropan-1-amine Chemical compound CC[C@@H](N)C1=CC=CC=C1 AQFLVLHRZFLDDV-SECBINFHSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- ZQEBQGAAWMOMAI-SSDOTTSWSA-N (2r)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1C(O)=O ZQEBQGAAWMOMAI-SSDOTTSWSA-N 0.000 description 1
- FLWWDYNPWOSLEO-HQVZTVAUSA-N (2s)-2-[[4-[1-(2-amino-4-oxo-1h-pteridin-6-yl)ethyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1C(C)N(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FLWWDYNPWOSLEO-HQVZTVAUSA-N 0.000 description 1
- SQEFIXLBBMPINL-NSHDSACASA-N (2s)-2-[tert-butyl(dimethyl)silyl]oxy-1-pyrrolidin-1-ylpropan-1-one Chemical compound CC(C)(C)[Si](C)(C)O[C@@H](C)C(=O)N1CCCC1 SQEFIXLBBMPINL-NSHDSACASA-N 0.000 description 1
- IXHNFOOSLAWRBQ-UHFFFAOYSA-N (3,4-dichlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C(Cl)=C1 IXHNFOOSLAWRBQ-UHFFFAOYSA-N 0.000 description 1
- DIVNUTGTTIRPQA-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1OC DIVNUTGTTIRPQA-UHFFFAOYSA-N 0.000 description 1
- CGMTUJFWROPELF-YPAAEMCBSA-N (3E,5S)-5-[(2S)-butan-2-yl]-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione Chemical compound CC[C@H](C)[C@@H]1NC(=O)\C(=C(/C)O)C1=O CGMTUJFWROPELF-YPAAEMCBSA-N 0.000 description 1
- CFNAMLAVUTUGPM-SECBINFHSA-N (3r)-3-amino-3-(3,4-dichlorophenyl)propan-1-ol Chemical compound OCC[C@@H](N)C1=CC=C(Cl)C(Cl)=C1 CFNAMLAVUTUGPM-SECBINFHSA-N 0.000 description 1
- ACJWNKAQMZQVBW-MRVPVSSYSA-N (3r)-3-amino-3-(3,4-dichlorophenyl)propanoic acid Chemical compound OC(=O)C[C@@H](N)C1=CC=C(Cl)C(Cl)=C1 ACJWNKAQMZQVBW-MRVPVSSYSA-N 0.000 description 1
- KXSUPTABCNRBDK-MRXNPFEDSA-N (3s)-3-(4-chloro-3-fluorophenyl)-4-(methylamino)-1-[2-(propan-2-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]butan-1-one Chemical compound C1([C@H](CC(=O)N2CC3=NC(NC(C)C)=NC=C3CC2)CNC)=CC=C(Cl)C(F)=C1 KXSUPTABCNRBDK-MRXNPFEDSA-N 0.000 description 1
- VFTFNFNPDSHWFD-LLVKDONJSA-N (3s)-3-(4-chloro-3-fluorophenyl)-4-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoic acid Chemical compound CC(C)(C)OC(=O)N(C)C[C@@H](CC(O)=O)C1=CC=C(Cl)C(F)=C1 VFTFNFNPDSHWFD-LLVKDONJSA-N 0.000 description 1
- TVIRNGFXQVMMGB-OFWIHYRESA-N (3s,6r,10r,13e,16s)-16-[(2r,3r,4s)-4-chloro-3-hydroxy-4-phenylbutan-2-yl]-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H](O)[C@@H](Cl)C=2C=CC=CC=2)C/C=C/C(=O)N1 TVIRNGFXQVMMGB-OFWIHYRESA-N 0.000 description 1
- QDMNNMIOWVJVLY-QMMMGPOBSA-N (4r)-4-phenyl-1,3-oxazolidin-2-one Chemical compound C1OC(=O)N[C@@H]1C1=CC=CC=C1 QDMNNMIOWVJVLY-QMMMGPOBSA-N 0.000 description 1
- YMVGXIZVSPMNPD-NSHDSACASA-N (4s)-3-acetyl-4-benzyl-1,3-oxazolidin-2-one Chemical compound C1OC(=O)N(C(=O)C)[C@H]1CC1=CC=CC=C1 YMVGXIZVSPMNPD-NSHDSACASA-N 0.000 description 1
- XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
- XRBSKUSTLXISAB-UHFFFAOYSA-N (7R,7'R,8R,8'R)-form-Podophyllic acid Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C(CO)C2C(O)=O)=C1 XRBSKUSTLXISAB-UHFFFAOYSA-N 0.000 description 1
- JXVAMODRWBNUSF-KZQKBALLSA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-5-[[(2s,4as,5as,7s,9s,9ar,10ar)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-10-[(2s,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2 Chemical compound O([C@@H]1C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C2[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H]4O[C@@H]5O[C@@H](C)C(=O)C[C@@H]5O[C@H]4C3)[C@H](C2)N(C)C)C[C@]1(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 JXVAMODRWBNUSF-KZQKBALLSA-N 0.000 description 1
- INAUWOVKEZHHDM-PEDBPRJASA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 INAUWOVKEZHHDM-PEDBPRJASA-N 0.000 description 1
- NOPNWHSMQOXAEI-PUCKCBAPSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-(2,3-dihydropyrrol-1-yl)-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCC=C1 NOPNWHSMQOXAEI-PUCKCBAPSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 description 1
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 description 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- URWHLPSYCBLLIL-GFCCVEGCSA-N (R)-(3-chloro-4-fluorophenyl)-cyclopentylmethanamine Chemical compound N[C@H](C1CCCC1)c1ccc(F)c(Cl)c1 URWHLPSYCBLLIL-GFCCVEGCSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical class C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 1
- BKMMTJMQCTUHRP-VKHMYHEASA-N (S)-2-aminopropan-1-ol Chemical compound C[C@H](N)CO BKMMTJMQCTUHRP-VKHMYHEASA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical group C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical group C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- VLBUERZRFSORRZ-UHFFFAOYSA-N 1,3-benzothiazol-2-ylmethanamine Chemical compound C1=CC=C2SC(CN)=NC2=C1 VLBUERZRFSORRZ-UHFFFAOYSA-N 0.000 description 1
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3h-pyrrolo[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- NXSULSSADMIWQD-UHFFFAOYSA-N 1-(1h-benzimidazol-2-yl)ethanamine Chemical compound C1=CC=C2NC(C(N)C)=NC2=C1 NXSULSSADMIWQD-UHFFFAOYSA-N 0.000 description 1
- MYBLAOJMRYYKMS-RTRLPJTCSA-N 1-(2-chloroethyl)-1-nitroso-3-[(3r,4r,5s,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea Chemical compound OC[C@H]1OC(O)[C@H](NC(=O)N(CCCl)N=O)[C@@H](O)[C@@H]1O MYBLAOJMRYYKMS-RTRLPJTCSA-N 0.000 description 1
- LVAQDAHAPUCCNJ-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-2,2,2-trifluoroethanamine Chemical compound FC(F)(F)C(N)C1=CC=C(Cl)C(Cl)=C1 LVAQDAHAPUCCNJ-UHFFFAOYSA-N 0.000 description 1
- HNSNOOGMEHXJFE-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-n-[(3,4-dimethoxyphenyl)methyl]-2,2,2-trifluoroethanamine Chemical compound C1=C(OC)C(OC)=CC=C1CNC(C(F)(F)F)C1=CC=C(Cl)C(Cl)=C1 HNSNOOGMEHXJFE-UHFFFAOYSA-N 0.000 description 1
- FKGDMSJKLIQBQS-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)propan-1-one Chemical compound CCC(=O)C1=CC=C(Cl)C(Cl)=C1 FKGDMSJKLIQBQS-UHFFFAOYSA-N 0.000 description 1
- QHARBBFZGIDKLK-UHFFFAOYSA-N 1-(3-chloro-4-fluorophenyl)ethanamine Chemical compound CC(N)C1=CC=C(F)C(Cl)=C1 QHARBBFZGIDKLK-UHFFFAOYSA-N 0.000 description 1
- QNQUBGPYUVRMSB-UHFFFAOYSA-N 1-(4-chloro-3-fluorophenyl)propan-1-amine Chemical group CCC(N)C1=CC=C(Cl)C(F)=C1 QNQUBGPYUVRMSB-UHFFFAOYSA-N 0.000 description 1
- QGCLEUGNYRXBMZ-UHFFFAOYSA-N 1-(4-fluorophenyl)ethanamine Chemical compound CC(N)C1=CC=C(F)C=C1 QGCLEUGNYRXBMZ-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- AGXASUCVOQMLCW-ONEGZZNKSA-N 1-chloro-2-fluoro-4-[(e)-2-nitroethenyl]benzene Chemical compound [O-][N+](=O)\C=C\C1=CC=C(Cl)C(F)=C1 AGXASUCVOQMLCW-ONEGZZNKSA-N 0.000 description 1
- 125000001478 1-chloroethyl group Chemical group [H]C([H])([H])C([H])(Cl)* 0.000 description 1
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 1
- ALOCUZOKRULSAA-UHFFFAOYSA-N 1-methylpiperidin-4-amine Chemical group CN1CCC(N)CC1 ALOCUZOKRULSAA-UHFFFAOYSA-N 0.000 description 1
- QUYJEYSRBCLJIZ-UHFFFAOYSA-N 1-methylpyrazole-3-carbaldehyde Chemical compound CN1C=CC(C=O)=N1 QUYJEYSRBCLJIZ-UHFFFAOYSA-N 0.000 description 1
- DGHHQBMTXTWTJV-BQAIUKQQSA-N 119413-54-6 Chemical compound Cl.C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 DGHHQBMTXTWTJV-BQAIUKQQSA-N 0.000 description 1
- 238000004293 19F NMR spectroscopy Methods 0.000 description 1
- UAYYSAPJTRVEQA-UHFFFAOYSA-N 1h-indol-5-ylmethanamine Chemical compound NCC1=CC=C2NC=CC2=C1 UAYYSAPJTRVEQA-UHFFFAOYSA-N 0.000 description 1
- FURRUNQWZZOXOT-UHFFFAOYSA-N 1h-indol-6-ylmethanamine Chemical compound NCC1=CC=C2C=CNC2=C1 FURRUNQWZZOXOT-UHFFFAOYSA-N 0.000 description 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
- BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- SSNMISUJOQAFRR-UHFFFAOYSA-N 2,6-naphthyridine Chemical compound N1=CC=C2C=NC=CC2=C1 SSNMISUJOQAFRR-UHFFFAOYSA-N 0.000 description 1
- VSFLNSYRZPIDIL-UHFFFAOYSA-N 2-(4-fluoroanilino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxylic acid Chemical compound N1=C2CN(C(=O)O)CCC2=CN=C1NC1=CC=C(F)C=C1 VSFLNSYRZPIDIL-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical class OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- BVWFQDRDIOUDHP-UHFFFAOYSA-N 2-(benzylamino)ethyl acetate Chemical compound CC(=O)OCCNCC1=CC=CC=C1 BVWFQDRDIOUDHP-UHFFFAOYSA-N 0.000 description 1
- AERHQVIADZNUCA-UHFFFAOYSA-N 2-(oxan-4-yl)guanidine Chemical compound NC(=N)NC1CCOCC1 AERHQVIADZNUCA-UHFFFAOYSA-N 0.000 description 1
- WXUMCUVLCGGXPH-LJQANCHMSA-N 2-(oxan-4-ylamino)-N-[(1R)-1-phenylpropyl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound N([C@H](CC)C=1C=CC=CC=1)C(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 WXUMCUVLCGGXPH-LJQANCHMSA-N 0.000 description 1
- WXNWWJWVBQNCJX-UHFFFAOYSA-N 2-[(1-methyl-6-oxopyridin-3-yl)amino]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylic acid Chemical compound Cn1cc(Nc2ncc3CCN(Cc3n2)C(O)=O)ccc1=O WXNWWJWVBQNCJX-UHFFFAOYSA-N 0.000 description 1
- VYUWBWJYXQSVHQ-OAHLLOKOSA-N 2-[(1r)-1-(3,4-dichlorophenyl)propyl]isoindole-1,3-dione Chemical compound C1([C@H](N2C(C3=CC=CC=C3C2=O)=O)CC)=CC=C(Cl)C(Cl)=C1 VYUWBWJYXQSVHQ-OAHLLOKOSA-N 0.000 description 1
- WUJOMIPWVWYBFM-LJQANCHMSA-N 2-[(1s)-2-[tert-butyl(dimethyl)silyl]oxy-1-(4-chloro-3-fluorophenyl)ethyl]isoindole-1,3-dione Chemical compound C1([C@H](N2C(C3=CC=CC=C3C2=O)=O)CO[Si](C)(C)C(C)(C)C)=CC=C(Cl)C(F)=C1 WUJOMIPWVWYBFM-LJQANCHMSA-N 0.000 description 1
- GTEXIOINCJRBIO-UHFFFAOYSA-N 2-[2-(dimethylamino)ethoxy]-n,n-dimethylethanamine Chemical compound CN(C)CCOCCN(C)C GTEXIOINCJRBIO-UHFFFAOYSA-N 0.000 description 1
- NLLNVUMNDCNCQY-UHFFFAOYSA-N 2-[tert-butyl(dimethyl)silyl]oxy-n-methoxy-n-methylacetamide Chemical compound CON(C)C(=O)CO[Si](C)(C)C(C)(C)C NLLNVUMNDCNCQY-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- BPNNVLOEKGJJJI-UHFFFAOYSA-N 2-amino-2-(4-chloro-3-fluorophenyl)acetic acid Chemical compound OC(=O)C(N)C1=CC=C(Cl)C(F)=C1 BPNNVLOEKGJJJI-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 1
- FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 1
- FDAYLTPAFBGXAB-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)ethanamine Chemical compound ClCCN(CCCl)CCCl FDAYLTPAFBGXAB-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- YJVXEQJVAOGXKM-UHFFFAOYSA-N 2-ethoxy-2h-quinoline-1-carboxylic acid Chemical compound C1=CC=C2N(C(O)=O)C(OCC)C=CC2=C1 YJVXEQJVAOGXKM-UHFFFAOYSA-N 0.000 description 1
- HQWDKLAIDBOLFE-UHFFFAOYSA-M 2-fluoro-1-methylpyridin-1-ium;4-methylbenzenesulfonate Chemical compound C[N+]1=CC=CC=C1F.CC1=CC=C(S([O-])(=O)=O)C=C1 HQWDKLAIDBOLFE-UHFFFAOYSA-M 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- SXRPUYKJGVYYIF-UHFFFAOYSA-N 2-methyl-N-(1H-pyrazol-4-ylmethylidene)propane-2-sulfinamide Chemical compound CC(C)(C)S(=O)N=CC=1C=NNC=1 SXRPUYKJGVYYIF-UHFFFAOYSA-N 0.000 description 1
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 1
- RAJRANFZSWDUJZ-UHFFFAOYSA-N 2-methylpyrazole-3-carbaldehyde Chemical compound CN1N=CC=C1C=O RAJRANFZSWDUJZ-UHFFFAOYSA-N 0.000 description 1
- LGEXGKUJMFHVSY-UHFFFAOYSA-N 2-n,4-n,6-n-trimethyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(NC)=NC(NC)=N1 LGEXGKUJMFHVSY-UHFFFAOYSA-N 0.000 description 1
- PIAOLBVUVDXHHL-UHFFFAOYSA-N 2-nitroethenylbenzene Chemical compound [O-][N+](=O)C=CC1=CC=CC=C1 PIAOLBVUVDXHHL-UHFFFAOYSA-N 0.000 description 1
- UZEKTDVGUQCDBI-UHFFFAOYSA-N 2-propan-2-ylguanidine Chemical compound CC(C)NC(N)=N UZEKTDVGUQCDBI-UHFFFAOYSA-N 0.000 description 1
- UHWHYRJXUNAUJR-UHFFFAOYSA-N 2-propan-2-ylguanidine;hydrochloride Chemical compound Cl.CC(C)NC(N)=N UHWHYRJXUNAUJR-UHFFFAOYSA-N 0.000 description 1
- YIMDLWDNDGKDTJ-QLKYHASDSA-N 3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-QLKYHASDSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
- ZVIQXFUBNNGOJY-UHFFFAOYSA-N 3-fluoro-4-(trifluoromethyl)benzaldehyde Chemical compound FC1=CC(C=O)=CC=C1C(F)(F)F ZVIQXFUBNNGOJY-UHFFFAOYSA-N 0.000 description 1
- DPDAEMNQJYDHRQ-UHFFFAOYSA-N 3-fluoro-4-(trifluoromethyl)benzoyl chloride Chemical compound FC1=CC(C(Cl)=O)=CC=C1C(F)(F)F DPDAEMNQJYDHRQ-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- DJBIUAXIJDEEHV-UHFFFAOYSA-N 4-(4-chloro-3-fluorophenyl)piperidin-4-amine Chemical compound C=1C=C(Cl)C(F)=CC=1C1(N)CCNCC1 DJBIUAXIJDEEHV-UHFFFAOYSA-N 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- IKMGPYIIYSMTRZ-UHFFFAOYSA-N 4-(aminomethyl)-2-(trifluoromethyl)benzonitrile Chemical compound NCC1=CC=C(C#N)C(C(F)(F)F)=C1 IKMGPYIIYSMTRZ-UHFFFAOYSA-N 0.000 description 1
- GIWYZIJRRJPYQS-UHFFFAOYSA-N 4-(aminomethyl)-2-chlorobenzonitrile;hydrochloride Chemical compound Cl.NCC1=CC=C(C#N)C(Cl)=C1 GIWYZIJRRJPYQS-UHFFFAOYSA-N 0.000 description 1
- QREAXVRKRXUJKQ-UHFFFAOYSA-N 4-(aminomethyl)-2-fluorobenzonitrile Chemical compound NCC1=CC=C(C#N)C(F)=C1 QREAXVRKRXUJKQ-UHFFFAOYSA-N 0.000 description 1
- ZWCXOJYJJINQGU-UHFFFAOYSA-N 4-(difluoromethoxy)benzaldehyde Chemical compound FC(F)OC1=CC=C(C=O)C=C1 ZWCXOJYJJINQGU-UHFFFAOYSA-N 0.000 description 1
- IMLXLGZJLAOKJN-UHFFFAOYSA-N 4-aminocyclohexan-1-ol Chemical compound NC1CCC(O)CC1 IMLXLGZJLAOKJN-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- AGYWDGVTLKNTBS-UHFFFAOYSA-N 4-bromo-1-chloro-2-fluorobenzene Chemical group FC1=CC(Br)=CC=C1Cl AGYWDGVTLKNTBS-UHFFFAOYSA-N 0.000 description 1
- SBSFDYRKNUCGBZ-UHFFFAOYSA-N 4-bromo-2-fluoro-1-(trifluoromethoxy)benzene Chemical compound FC1=CC(Br)=CC=C1OC(F)(F)F SBSFDYRKNUCGBZ-UHFFFAOYSA-N 0.000 description 1
- JPNOSHZBKVMMSB-UHFFFAOYSA-N 4-bromo-3-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC(C=O)=CC=C1Br JPNOSHZBKVMMSB-UHFFFAOYSA-N 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-M 4-nitrobenzoate Chemical compound [O-]C(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-M 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
- WYPFXZXGRBDLFQ-UHFFFAOYSA-N 5,6,7,8-tetrahydro-2,6-naphthyridin-3-amine Chemical compound C1NCCC2=C1C=C(N)N=C2 WYPFXZXGRBDLFQ-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- OVHGAUSICOZZFQ-UHFFFAOYSA-N 5-bromo-5,6-dichlorocyclohexa-1,3-diene Chemical group ClC1C=CC=CC1(Cl)Br OVHGAUSICOZZFQ-UHFFFAOYSA-N 0.000 description 1
- XDQQMFWLPCXXNV-UHFFFAOYSA-N 6,7-dihydro-5h-pyrano[2,3-d]pyrimidine Chemical group C1=NC=C2CCCOC2=N1 XDQQMFWLPCXXNV-UHFFFAOYSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- ZZQSZRUNQPTIHD-UHFFFAOYSA-N 7H-pyrano[2,3-d]pyrimidine-7-carboxylic acid Chemical compound N1=CN=CC2=C1OC(C=C2)C(=O)O ZZQSZRUNQPTIHD-UHFFFAOYSA-N 0.000 description 1
- JRKLRIAIMIKGHT-UHFFFAOYSA-N 8-bromoquinoline-4-carbaldehyde Chemical compound C1=CN=C2C(Br)=CC=CC2=C1C=O JRKLRIAIMIKGHT-UHFFFAOYSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N Alternaria alternata Crofton-weed toxin Natural products CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 108090000644 Angiozyme Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- QKZVTXAXHSYQQZ-UHFFFAOYSA-N C1=C(C#N)C(Cl)=CC(CNC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)=C1 Chemical compound C1=C(C#N)C(Cl)=CC(CNC(=O)N2CC3=NC(NC4CCOCC4)=NC=C3CC2)=C1 QKZVTXAXHSYQQZ-UHFFFAOYSA-N 0.000 description 1
- UYQNCFXKGDEPAH-UHFFFAOYSA-N C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NC1CN(C)CC1C1=CC=C(F)C(F)=C1 Chemical compound C1C2=NC(NC(C)C)=NC=C2CCN1C(=O)NC1CN(C)CC1C1=CC=C(F)C(F)=C1 UYQNCFXKGDEPAH-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical class [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229930188224 Cryptophycin Natural products 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical class OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical class [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- AUGQEEXBDZWUJY-ZLJUKNTDSA-N Diacetoxyscirpenol Chemical compound C([C@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)C)O2 AUGQEEXBDZWUJY-ZLJUKNTDSA-N 0.000 description 1
- AUGQEEXBDZWUJY-UHFFFAOYSA-N Diacetoxyscirpenol Natural products CC(=O)OCC12CCC(C)=CC1OC1C(O)C(OC(C)=O)C2(C)C11CO1 AUGQEEXBDZWUJY-UHFFFAOYSA-N 0.000 description 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 238000005642 Gabriel synthesis reaction Methods 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical class C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical class [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- JLERVPBPJHKRBJ-UHFFFAOYSA-N LY 117018 Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCC3)=CC=2)C2=CC=C(O)C=C2S1 JLERVPBPJHKRBJ-UHFFFAOYSA-N 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical class [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010027540 Microcytosis Diseases 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- ZXONXRXDEVYWHO-OAHLLOKOSA-N N([C@H](C)C=1C=C(Cl)C(Cl)=CC=1)C(=O)N(CC1=N2)CCC1=CN=C2NCCN1CCOCC1 Chemical compound N([C@H](C)C=1C=C(Cl)C(Cl)=CC=1)C(=O)N(CC1=N2)CCC1=CN=C2NCCN1CCOCC1 ZXONXRXDEVYWHO-OAHLLOKOSA-N 0.000 description 1
- OARZAMNROKRYNC-LJQANCHMSA-N N([C@H](CC)C=1C=CC(F)=CC=1)C(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 Chemical compound N([C@H](CC)C=1C=CC(F)=CC=1)C(=O)N(CC1=N2)CCC1=CN=C2NC1CCOCC1 OARZAMNROKRYNC-LJQANCHMSA-N 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- WNEZDNJIZNFGBU-UHFFFAOYSA-N N-[1-(3,4-dichlorophenyl)ethyl]-2-[(3-hydroxycyclobutyl)amino]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C)NC(=O)N(CC1=N2)CCC1=CN=C2NC1CC(O)C1 WNEZDNJIZNFGBU-UHFFFAOYSA-N 0.000 description 1
- LEPKQLRPBXTUBE-UHFFFAOYSA-N N-[1-(3,4-dichlorophenyl)ethyl]-7-methyl-2-(oxan-4-ylamino)-6,8-dihydro-5H-quinazoline-7-carboxamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C)NC(=O)C(CC1=N2)(C)CCC1=CN=C2NC1CCOCC1 LEPKQLRPBXTUBE-UHFFFAOYSA-N 0.000 description 1
- HIUZCDVEQRAIPE-UHFFFAOYSA-N N-[1-(4-chloro-3-fluorophenyl)ethyl]-2-(oxan-4-ylamino)-5,6,7,8-tetrahydroquinazoline-7-carboxamide Chemical compound C=1C=C(Cl)C(F)=CC=1C(C)NC(=O)C(CC1=N2)CCC1=CN=C2NC1CCOCC1 HIUZCDVEQRAIPE-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- WXOMTJVVIMOXJL-BOBFKVMVSA-A O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O Chemical class O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O WXOMTJVVIMOXJL-BOBFKVMVSA-A 0.000 description 1
- 229930187135 Olivomycin Natural products 0.000 description 1
- VREZDOWOLGNDPW-ALTGWBOUSA-N Pancratistatin Chemical compound C1=C2[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H]3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-ALTGWBOUSA-N 0.000 description 1
- VREZDOWOLGNDPW-MYVCAWNPSA-N Pancratistatin Natural products O=C1N[C@H]2[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@H]2c2c1c(O)c1OCOc1c2 VREZDOWOLGNDPW-MYVCAWNPSA-N 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Porfiromycine Chemical compound O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 1
- 101710109947 Protein kinase C alpha type Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 1
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 1
- BXFOFFBJRFZBQZ-QYWOHJEZSA-N T-2 toxin Chemical compound C([C@@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@H]1[C@]3(COC(C)=O)C[C@@H](C(=C1)C)OC(=O)CC(C)C)O2 BXFOFFBJRFZBQZ-QYWOHJEZSA-N 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- CGMTUJFWROPELF-UHFFFAOYSA-N Tenuazonic acid Natural products CCC(C)C1NC(=O)C(=C(C)/O)C1=O CGMTUJFWROPELF-UHFFFAOYSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- FYAMXEPQQLNQDM-UHFFFAOYSA-N Tris(1-aziridinyl)phosphine oxide Chemical compound C1CN1P(N1CC1)(=O)N1CC1 FYAMXEPQQLNQDM-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZYVSOIYQKUDENJ-ASUJBHBQSA-N [(2R,3R,4R,6R)-6-[[(6S,7S)-6-[(2S,4R,5R,6R)-4-[(2R,4R,5R,6R)-4-[(2S,4S,5S,6S)-5-acetyloxy-4-hydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-7-[(3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-4,10-dihydroxy-3-methyl-5-oxo-7,8-dihydro-6H-anthracen-2-yl]oxy]-4-[(2R,4R,5R,6R)-4-hydroxy-5-methoxy-6-methyloxan-2-yl]oxy-2-methyloxan-3-yl] acetate Chemical class COC([C@@H]1Cc2cc3cc(O[C@@H]4C[C@@H](O[C@@H]5C[C@@H](O)[C@@H](OC)[C@@H](C)O5)[C@H](OC(C)=O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@@H](OC(C)=O)[C@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O ZYVSOIYQKUDENJ-ASUJBHBQSA-N 0.000 description 1
- SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
- IHGLINDYFMDHJG-UHFFFAOYSA-N [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC=CC=C11)=C1C(=O)C(C=C1)=CC=C1OCCN1CCCC1 IHGLINDYFMDHJG-UHFFFAOYSA-N 0.000 description 1
- DEDJLOJSCVKUHI-UHFFFAOYSA-N [3-fluoro-4-(trifluoromethoxy)phenyl]-(1,3-oxazol-5-yl)methanamine;hydrochloride Chemical compound Cl.C=1C=C(OC(F)(F)F)C(F)=CC=1C(N)C1=CN=CO1 DEDJLOJSCVKUHI-UHFFFAOYSA-N 0.000 description 1
- MGAYIHHTWUVPOJ-UHFFFAOYSA-N [Mg]C1=CC=C(Cl)C(Cl)=C1 Chemical compound [Mg]C1=CC=C(Cl)C(Cl)=C1 MGAYIHHTWUVPOJ-UHFFFAOYSA-N 0.000 description 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 229940028652 abraxane Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- ZOZKYEHVNDEUCO-XUTVFYLZSA-N aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 1
- 229950002684 aceglatone Drugs 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 1
- 229950004955 adozelesin Drugs 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 201000007538 anal carcinoma Diseases 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940045713 antineoplastic alkylating drug ethylene imines Drugs 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- 229940087620 aromasin Drugs 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 229950011321 azaserine Drugs 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940056854 bio-statin Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 229950006844 bizelesin Drugs 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001649 bromium compounds Chemical group 0.000 description 1
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 1
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- ICFZVGUJHMPRKR-UHFFFAOYSA-N butane-1,1,4-tricarboxylic acid Chemical compound OC(=O)CCCC(C(O)=O)C(O)=O ICFZVGUJHMPRKR-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-L carboxylato carbonate Chemical compound [O-]C(=O)OC([O-])=O ZFTFAPZRGNKQPU-UHFFFAOYSA-L 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- BBZDXMBRAFTCAA-AREMUKBSSA-N carzelesin Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 1
- 229950007509 carzelesin Drugs 0.000 description 1
- 108010047060 carzinophilin Proteins 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
- 229960001480 chlorozotocin Drugs 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 108010006226 cryptophycin Proteins 0.000 description 1
- 108010089438 cryptophycin 1 Proteins 0.000 description 1
- 108010090203 cryptophycin 8 Proteins 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000008049 diazo compounds Chemical class 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 125000006003 dichloroethyl group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004212 difluorophenyl group Chemical group 0.000 description 1
- BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- XOPYFXBZMVTEJF-PDACKIITSA-N eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 description 1
- XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 description 1
- 229950000549 elliptinium acetate Drugs 0.000 description 1
- 229940120655 eloxatin Drugs 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N eniluracil Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- 229950010213 eniluracil Drugs 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229950002973 epitiostanol Drugs 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
- 229950002017 esorubicin Drugs 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- VMYQJDCENDEETH-UHFFFAOYSA-N ethyl 2-[tert-butyl(dimethyl)silyl]oxyacetate Chemical compound CCOC(=O)CO[Si](C)(C)C(C)(C)C VMYQJDCENDEETH-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229920001038 ethylene copolymer Polymers 0.000 description 1
- 229960005237 etoglucid Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 229940043168 fareston Drugs 0.000 description 1
- 229940087861 faslodex Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- XZBIXDPGRMLSTC-UHFFFAOYSA-N formohydrazide Chemical compound NNC=O XZBIXDPGRMLSTC-UHFFFAOYSA-N 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229940020967 gemzar Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- VHHHONWQHHHLTI-UHFFFAOYSA-N hexachloroethane Chemical compound ClC(Cl)(Cl)C(Cl)(Cl)Cl VHHHONWQHHHLTI-UHFFFAOYSA-N 0.000 description 1
- 125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- KLEAIHJJLUAXIQ-JDRGBKBRSA-N irinotecan hydrochloride hydrate Chemical compound O.O.O.Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 KLEAIHJJLUAXIQ-JDRGBKBRSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940116871 l-lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 229950008745 losoxantrone Drugs 0.000 description 1
- 238000003819 low-pressure liquid chromatography Methods 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- RVFGKBWWUQOIOU-NDEPHWFRSA-N lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
- 229950002654 lurtotecan Drugs 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- LVKCSZQWLOVUGB-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].C[CH-]C LVKCSZQWLOVUGB-UHFFFAOYSA-M 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical class [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960002868 mechlorethamine hydrochloride Drugs 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 229950009246 mepitiostane Drugs 0.000 description 1
- 238000003328 mesylation reaction Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- LGRLWUINFJPLSH-UHFFFAOYSA-N methanide Chemical compound [CH3-] LGRLWUINFJPLSH-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- LPEKGGXMPWTOCB-VKHMYHEASA-N methyl (S)-lactate Chemical compound COC(=O)[C@H](C)O LPEKGGXMPWTOCB-VKHMYHEASA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical class COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- AQIAIZBHFAKICS-UHFFFAOYSA-N methylaminomethyl Chemical compound [CH2]NC AQIAIZBHFAKICS-UHFFFAOYSA-N 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- WIXXOCCJPBPLGM-YVEFUNNKSA-N n-[(1r)-1-(3,4-dichlorophenyl)propyl]-2-[[(2s)-1-hydroxypropan-2-yl]amino]-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1([C@H](NC(=O)N2CC3=NC(N[C@@H](C)CO)=NC=C3CC2)CC)=CC=C(Cl)C(Cl)=C1 WIXXOCCJPBPLGM-YVEFUNNKSA-N 0.000 description 1
- QGJUHTFRVIOKPG-UHFFFAOYSA-N n-[(3,4-dicyanophenyl)methyl]-2-(oxan-4-ylamino)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxamide Chemical compound C1CC2=CN=C(NC3CCOCC3)N=C2CN1C(=O)NCC1=CC=C(C#N)C(C#N)=C1 QGJUHTFRVIOKPG-UHFFFAOYSA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical group NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229950006327 napsilate Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 230000011234 negative regulation of signal transduction Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 229940080607 nexavar Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Chemical class 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- AKRYBBWYDSDZHG-UHFFFAOYSA-N nitrosobis(2-oxopropyl)amine Chemical compound CC(=O)CN(N=O)CC(C)=O AKRYBBWYDSDZHG-UHFFFAOYSA-N 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 229940085033 nolvadex Drugs 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical class O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical class OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical compound NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 description 1
- 125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- VREZDOWOLGNDPW-UHFFFAOYSA-N pancratistatine Natural products C1=C2C3C(O)C(O)C(O)C(O)C3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000030940 penile carcinoma Diseases 0.000 description 1
- 201000008174 penis carcinoma Diseases 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000005543 phthalimide group Chemical group 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- DWIPRWPIPUAHJN-UHFFFAOYSA-N pyrimidin-5-ol;hydrochloride Chemical compound Cl.OC1=CN=CN=C1 DWIPRWPIPUAHJN-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229940099538 rapamune Drugs 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229950004892 rodorubicin Drugs 0.000 description 1
- MBABCNBNDNGODA-WPZDJQSSSA-N rolliniastatin 1 Natural products O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@H]1[C@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-WPZDJQSSSA-N 0.000 description 1
- NSFWWJIQIKBZMJ-PAGWOCKZSA-N roridin a Chemical compound C([C@@]12[C@]3(C)[C@H]4C[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)[C@@H](O)[C@H](C)CCO[C@H](\C=C\C=C/C(=O)O4)[C@H](O)C)O2 NSFWWJIQIKBZMJ-PAGWOCKZSA-N 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000011452 sequencing regimen Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 229950006315 spirogermanium Drugs 0.000 description 1
- ICXJVZHDZFXYQC-UHFFFAOYSA-N spongistatin 1 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C ICXJVZHDZFXYQC-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical class [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229960003454 tamoxifen citrate Drugs 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- CESUXLKAADQNTB-UHFFFAOYSA-N tert-butanesulfinamide Chemical compound CC(C)(C)S(N)=O CESUXLKAADQNTB-UHFFFAOYSA-N 0.000 description 1
- HBSFZMBVXUIIMS-UXHICEINSA-N tert-butyl (2R)-2-[(S)-(1,3-dioxoisoindol-2-yl)-[3-fluoro-4-(trifluoromethyl)phenyl]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1[C@@H](N1C(=O)c2ccccc2C1=O)c1ccc(c(F)c1)C(F)(F)F HBSFZMBVXUIIMS-UXHICEINSA-N 0.000 description 1
- ULKNWUBRZYTTPC-CYBMUJFWSA-N tert-butyl (2r)-2-[3-fluoro-4-(trifluoromethyl)benzoyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1C(=O)C1=CC=C(C(F)(F)F)C(F)=C1 ULKNWUBRZYTTPC-CYBMUJFWSA-N 0.000 description 1
- NGQVZQWJIBUMKE-SNVBAGLBSA-N tert-butyl (4s)-4-(4-chloro-3-fluorophenyl)-2-oxopyrrolidine-1-carboxylate Chemical compound C1C(=O)N(C(=O)OC(C)(C)C)C[C@@H]1C1=CC=C(Cl)C(F)=C1 NGQVZQWJIBUMKE-SNVBAGLBSA-N 0.000 description 1
- KWNDKZADLGFSKE-UHFFFAOYSA-N tert-butyl 3,5-dioxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(=O)CC(=O)C1 KWNDKZADLGFSKE-UHFFFAOYSA-N 0.000 description 1
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- FQIWHPALNIWULM-UHFFFAOYSA-N thiomorpholine-2,3-dione Chemical compound O=C1NCCSC1=O FQIWHPALNIWULM-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 125000005881 triazolinyl group Chemical group 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 150000008648 triflates Chemical class 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- JSPLKZUTYZBBKA-UHFFFAOYSA-N trioxidane Chemical compound OOO JSPLKZUTYZBBKA-UHFFFAOYSA-N 0.000 description 1
- 229950000212 trioxifene Drugs 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical group C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 description 1
- RXRGZNYSEHTMHC-BQBZGAKWSA-N troxacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)OC1 RXRGZNYSEHTMHC-BQBZGAKWSA-N 0.000 description 1
- 229950010147 troxacitabine Drugs 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229940094060 tykerb Drugs 0.000 description 1
- GFNNBHLJANVSQV-UHFFFAOYSA-N tyrphostin AG 1478 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1 GFNNBHLJANVSQV-UHFFFAOYSA-N 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 229950000578 vatalanib Drugs 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161447587P | 2011-02-28 | 2011-02-28 | |
| US201161447587P | 2011-02-28 | ||
| PCT/US2012/027009 WO2012118850A1 (en) | 2011-02-28 | 2012-02-28 | Serine/threonine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2543050T3 true ES2543050T3 (es) | 2015-08-14 |
Family
ID=45852719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12709429.0T Active ES2543050T3 (es) | 2011-02-28 | 2012-02-28 | Inhibidores de serina/treonina quinasa |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9133187B2 (enExample) |
| EP (1) | EP2681215B1 (enExample) |
| JP (1) | JP6085866B2 (enExample) |
| KR (1) | KR101961500B1 (enExample) |
| CN (1) | CN103635472B (enExample) |
| BR (1) | BR112013021896A2 (enExample) |
| CA (1) | CA2828478C (enExample) |
| ES (1) | ES2543050T3 (enExample) |
| MX (1) | MX339873B (enExample) |
| RU (1) | RU2013143839A (enExample) |
| WO (1) | WO2012118850A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101961500B1 (ko) | 2011-02-28 | 2019-03-22 | 어레이 바이오파마 인크. | 세린/트레오닌 키나제 억제제 |
| CA2839699A1 (en) | 2011-06-24 | 2012-12-27 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
| AU2012272898A1 (en) | 2011-06-24 | 2013-04-11 | Amgen Inc. | TRPM8 antagonists and their use in treatments |
| RU2014108140A (ru) | 2011-08-04 | 2015-09-10 | Эррэй Биофарма Инк. | Соединение на основе хинозолина в качестве ингибиторов серен-треониновых киназ |
| JP6089045B2 (ja) * | 2011-12-27 | 2017-03-01 | バイオ−ファーム ソリューションズ カンパニー リミテッド | 痛みの緩和または治療に使用するためのフェニルカルバメート化合物 |
| UA116774C2 (uk) | 2012-03-01 | 2018-05-10 | Еррей Біофарма Інк. | Інгібітори серин/треонінкінази |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| KR20150047597A (ko) | 2012-08-27 | 2015-05-04 | 어레이 바이오파마 인크. | 과증식성 질환의 치료를 위한 세린/트레오닌 키나아제 억제제 |
| BR112015005982A2 (pt) | 2012-09-19 | 2017-07-04 | Novartis Ag | di-hidropirrolidino-pirimidinas como inibidores de quinase |
| RU2015114936A (ru) | 2012-10-16 | 2016-12-10 | Ф. Хоффманн-Ля Рош Аг | Ингибиторы серин/треонинкиназы |
| JPWO2015012328A1 (ja) * | 2013-07-24 | 2017-03-02 | 武田薬品工業株式会社 | 複素環化合物 |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| JP6449293B2 (ja) | 2013-12-06 | 2019-01-09 | ジェネンテック, インコーポレイテッド | セリン/トレオニンキナーゼ阻害剤 |
| JP6642942B2 (ja) | 2013-12-30 | 2020-02-12 | アレイ バイオファーマ、インコーポレイテッド | セリン/トレオニンキナーゼ阻害剤 |
| BR112016015235A2 (pt) | 2013-12-30 | 2017-08-08 | Genentech Inc | Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento |
| CN109072311A (zh) | 2016-04-15 | 2018-12-21 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
| MX382339B (es) * | 2016-05-18 | 2025-03-13 | Mirati Therapeutics Inc | Inhibidores g12c de kras. |
| CN111373055B (zh) | 2017-09-08 | 2024-07-23 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
| ES2967094T3 (es) | 2017-09-29 | 2024-04-26 | Mitsubishi Tanabe Pharma Corp | Compuesto de pirrolidina ópticamente activo y procedimiento de producción del mismo |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| US20210008047A1 (en) | 2018-02-13 | 2021-01-14 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| WO2020192750A1 (zh) | 2019-03-28 | 2020-10-01 | 江苏恒瑞医药股份有限公司 | 噻吩并杂环类衍生物、其制备方法及其在医药上的应用 |
| BR112021018924A2 (pt) | 2019-03-29 | 2022-02-01 | Jiangsu Hengrui Medicine Co | Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento |
| CN113825757B (zh) | 2019-05-24 | 2023-10-20 | 江苏恒瑞医药股份有限公司 | 取代的稠合双环类衍生物、其制备方法及其在医药上的应用 |
| WO2020238791A1 (zh) * | 2019-05-24 | 2020-12-03 | 江苏恒瑞医药股份有限公司 | 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| CN111170929A (zh) * | 2019-12-12 | 2020-05-19 | 北京达因高科儿童药物研究院有限公司 | 一种由末端烯烃制备β-氨基醇的方法 |
| ES3033417T3 (en) * | 2020-09-25 | 2025-08-04 | Janssen Pharmaceutica Nv | Cyclin-dependent kinase 7 (cdk7) non-covalent inhibitors |
| CN116437915B (zh) | 2020-09-29 | 2025-03-18 | 江苏恒瑞医药股份有限公司 | 一种吡咯并杂环类衍生物的晶型及其制备方法 |
| CN115040522B (zh) * | 2022-06-30 | 2024-02-06 | 牡丹江医学院 | 一种用于治疗肺癌的药物及其制备方法 |
| KR20250091232A (ko) * | 2022-10-25 | 2025-06-20 | 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 | 피페리디노피리미딘계 유도체, 이의 제조 방법 및 이의 의학적 응용 |
| IT202200024963A1 (it) * | 2022-12-05 | 2024-06-05 | Angelini Pharma S P A | Composti attivatori dei canali potassio Kv7.2/Kv7.3 |
| TW202535869A (zh) * | 2023-10-23 | 2025-09-16 | 大陸商上海拓界生物醫藥科技有限公司 | 一種含有噻唑基的哌啶并嘧啶類衍生物、其製備方法及其醫藥上的應用 |
| WO2025223512A1 (zh) * | 2024-04-24 | 2025-10-30 | 江苏恒瑞医药股份有限公司 | 一种二氢吡啶并嘧啶衍生物的可药用盐、结晶形式及用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5705502A (en) | 1993-10-01 | 1998-01-06 | Novartis Corporation | Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof |
| WO1995009847A1 (en) | 1993-10-01 | 1995-04-13 | Ciba-Geigy Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| BR9713863A (pt) | 1996-12-05 | 2000-03-14 | Amgen Inc | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processos de profilaxia ou tratamento, para abaixar as concentrações no plasma, para diminuir a produção de prostaglandinas, e, para diminuir a atividade de enzima ciclooxigenase |
| US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
| EP1261327B1 (en) | 2000-02-25 | 2005-04-27 | F.Hoffmann-La Roche Ag | Adenosine receptor modulators |
| WO2002088079A2 (en) * | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| WO2003099808A1 (en) | 2002-05-21 | 2003-12-04 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| ATE451369T1 (de) | 2002-07-15 | 2009-12-15 | Merck & Co Inc | Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes |
| US7419978B2 (en) * | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
| TW200533357A (en) | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| AU2005232745A1 (en) | 2004-04-13 | 2005-10-27 | Astellas Pharma Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
| PE20060426A1 (es) | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| WO2006021458A2 (en) | 2004-08-27 | 2006-03-02 | Gpc Biotech Ag | Pyrimidine derivatives |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| EP1871762A2 (en) | 2005-04-18 | 2008-01-02 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| WO2007028022A2 (en) * | 2005-09-01 | 2007-03-08 | Renovis, Inc. | Novel compounds as p2x7 modulators and uses thereof |
| US7572809B2 (en) | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| ATE485268T1 (de) | 2006-02-16 | 2010-11-15 | Schering Corp | Pyrrolidin-derivate als erk-hemmer |
| WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| DE102006035202A1 (de) | 2006-07-29 | 2008-01-31 | Lanxess Deutschland Gmbh | Konservierungsmittel auf Basis von Carbonsäureanhydriden |
| US20100292205A1 (en) | 2006-08-23 | 2010-11-18 | Pfizer Inc. | Pyrimidone Compounds As GSK-3 Inhibitors |
| US7897762B2 (en) * | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| EP2094682A2 (en) | 2006-12-22 | 2009-09-02 | Novartis AG | Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections |
| US8063066B2 (en) * | 2007-03-19 | 2011-11-22 | Takeda Pharmaceutical Company Limited | MAPK/ERK kinase inhibitors |
| WO2009011904A1 (en) * | 2007-07-19 | 2009-01-22 | Renovis, Inc. | Compounds useful as faah modulators and uses thereof |
| JP5611826B2 (ja) | 2007-09-04 | 2014-10-22 | ザ スクリプス リサーチ インスティテュート | タンパク質キナーゼ阻害剤としての置換されたピリミジニル−アミン |
| WO2009061761A2 (en) | 2007-11-06 | 2009-05-14 | E. I. Du Pont De Nemours And Company | Fungicidal heterocyclic amines |
| WO2009146034A2 (en) * | 2008-03-31 | 2009-12-03 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors and methods of use thereof |
| WO2009156484A2 (en) | 2008-06-27 | 2009-12-30 | Novartis Ag | Organic compounds |
| EP2361248B1 (en) | 2008-06-27 | 2018-09-19 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| WO2010077275A1 (en) | 2008-12-08 | 2010-07-08 | Arena Pharmaceuticals, Inc. | Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
| KR101961500B1 (ko) | 2011-02-28 | 2019-03-22 | 어레이 바이오파마 인크. | 세린/트레오닌 키나제 억제제 |
| RU2014108140A (ru) | 2011-08-04 | 2015-09-10 | Эррэй Биофарма Инк. | Соединение на основе хинозолина в качестве ингибиторов серен-треониновых киназ |
| UA116774C2 (uk) | 2012-03-01 | 2018-05-10 | Еррей Біофарма Інк. | Інгібітори серин/треонінкінази |
| KR20150047597A (ko) | 2012-08-27 | 2015-05-04 | 어레이 바이오파마 인크. | 과증식성 질환의 치료를 위한 세린/트레오닌 키나아제 억제제 |
-
2012
- 2012-02-28 KR KR1020137025269A patent/KR101961500B1/ko not_active Expired - Fee Related
- 2012-02-28 BR BR112013021896A patent/BR112013021896A2/pt not_active Application Discontinuation
- 2012-02-28 JP JP2013556817A patent/JP6085866B2/ja active Active
- 2012-02-28 EP EP20120709429 patent/EP2681215B1/en active Active
- 2012-02-28 WO PCT/US2012/027009 patent/WO2012118850A1/en not_active Ceased
- 2012-02-28 CA CA2828478A patent/CA2828478C/en not_active Expired - Fee Related
- 2012-02-28 ES ES12709429.0T patent/ES2543050T3/es active Active
- 2012-02-28 MX MX2013009877A patent/MX339873B/es active IP Right Grant
- 2012-02-28 CN CN201280020897.3A patent/CN103635472B/zh active Active
- 2012-02-28 US US14/002,079 patent/US9133187B2/en active Active
- 2012-02-28 RU RU2013143839/04A patent/RU2013143839A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MX339873B (es) | 2016-06-15 |
| US9133187B2 (en) | 2015-09-15 |
| CN103635472A (zh) | 2014-03-12 |
| KR20140014190A (ko) | 2014-02-05 |
| EP2681215B1 (en) | 2015-04-22 |
| CA2828478A1 (en) | 2012-09-07 |
| MX2013009877A (es) | 2014-02-11 |
| RU2013143839A (ru) | 2015-04-10 |
| JP6085866B2 (ja) | 2017-03-01 |
| JP2014506930A (ja) | 2014-03-20 |
| WO2012118850A1 (en) | 2012-09-07 |
| CN103635472B (zh) | 2018-01-12 |
| CA2828478C (en) | 2019-12-31 |
| BR112013021896A2 (pt) | 2016-11-08 |
| EP2681215A1 (en) | 2014-01-08 |
| US20130338140A1 (en) | 2013-12-19 |
| KR101961500B1 (ko) | 2019-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2543050T3 (es) | Inhibidores de serina/treonina quinasa | |
| AU2022201413B9 (en) | Fused ring compounds | |
| RU2644947C2 (ru) | Ингибиторы серин/треонин киназы для лечения гиперпролиферативных заболеваний | |
| JP6716586B2 (ja) | Fgfr4阻害剤としての二環式複素環 | |
| AU2017286380B2 (en) | Azabenzimidazole derivatives as PI3K beta inhibitors | |
| US8288381B2 (en) | N-9 substituted purine compounds, compositions and methods of use | |
| US8828990B2 (en) | N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use | |
| CN104144930A (zh) | 新的中氮茚化合物,它们的制备方法以及包含它们的药物组合物 | |
| CN103958502A (zh) | 作为丝氨酸/苏氨酸激酶抑制剂的喹唑啉化合物 | |
| US20150031674A1 (en) | Serine/threonine kinase inhibitors | |
| TW201516045A (zh) | 絲胺酸/蘇胺酸激酶抑制劑 | |
| HK1191010A (en) | Serine/threonine kinase inhibitors | |
| HK1191010B (en) | Serine/threonine kinase inhibitors | |
| TW202545531A (zh) | 氮—喹唑啉化合物之使用方法 | |
| BR122024023999A2 (pt) | Compostos e composição farmacêutica | |
| HK1172328B (en) | N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use |